

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 April 2004 (08.04.2004)

PCT

(10) International Publication Number
WO 2004/029041 A1

(51) International Patent Classification⁷: C07D 401/06,
401/14, A61K 31/4545, A61P 1/04, 11/00, 17/00, 19/02,
27/00, 29/00, 37/00

(21) International Application Number:
PCT/SE2003/001425

(22) International Filing Date:
12 September 2003 (12.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0202838-9 24 September 2002 (24.09.2002) SE

(71) Applicant (for all designated States except US): AS-
TRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): LUCKHURST,
Christopher [GB/GB]; AstraZeneca R & D Charnwood,
Bakewell Road, Loughborough, Leicestershire LE11 5RH
(GB). PERRY, Matthew [GB/GB]; AstraZeneca R &
D Charnwood, Bakewell Road, Loughborough, Leices-
tershire LE11 5RH (GB). SPRINGTHORPE, Brian
[GB/GB]; AstraZeneca R & D Charnwood, Bakewell
Road, Loughborough, Leicestershire LE11 5RH (GB).

(74) Agent: ASTRAZENECA AB; Global Intellectual Prop-
erty, S-151 85 Södertälje (SE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,

GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:


— as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES,
FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO
patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG,
ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT,
RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: NOVEL PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASE STATES



(57) Abstract: The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.

WO 2004/029041 A1

BEST AVAILABLE COPY

WO 2004/029041

PCT/SE2003/001425

Novel piperidine derivatives for use the treatment
of chemokine mediated disease states.

The present invention concerns piperidine derivatives having pharmaceutical activity, to processes for preparing such derivatives, to pharmaceutical compositions
5 comprising such derivatives and to the use of such derivatives as active therapeutic agents.

Pharmaceutically active piperidine derivatives are disclosed in WO99/38514, WO99/04794 and WO00/35877.

Histamine is a basic amine, 2-(4-imidazolyl)-ethylamine, and is formed from histidine by histidine decarboxylase. It is found in most tissues of the body, but is present
10 in high concentrations in the lung, skin and in the gastrointestinal tract. At the cellular level inflammatory cells such as mast cells and basophils store large amounts of histamine. It is recognised that the degranulation of mast cells and basophils and the subsequent release of histamine is a fundamental mechanism responsible for the clinical manifestation of an allergic process. Histamine produces its actions by an effect on specific histamine G-
15 protein coupled receptors, which are of three main types, H1, H2 and H3. Histamine H1 antagonists comprise the largest class of medications used in the treatment of patients with allergic disorders, such as rhinitis and urticaria. H1 antagonists are useful in controlling the allergic response by for example blocking the action of histamine on post-capillary venule smooth muscle, resulting in decreased vascular permeability, exudation and
20 oedema. The antagonists also produce blockade of the actions of histamine on the H1 receptors on c-type nociceptive nerve fibres, resulting in decreased itching and sneezing.

Viral infections are known to cause lung inflammation. It has been shown experimentally that the common cold increases mucosal output of eotaxin in the airways. Instillation of eotaxin into the nose can mimic some of the signs and symptoms of a
25 common cold. (See, Greiff L *et al* Allergy (1999) 54(11) 1204-8 [Experimental common cold increase mucosal output of eotaxin in atopic individuals] and Kawaguchi M *et al* Int. Arch. Allergy Immunol. (2000) 122 S1 44 [Expression of eotaxin by normal airway epithelial cells after virus A infection].)

Chemokines are chemotactic cytokines that are released by a wide variety of cells
30 to attract macrophages, T cells, eosinophils, basophils and neutrophils to sites of inflammation and also play a rôle in the maturation of cells of the immune system. Chemokines play an important rôle in immune and inflammatory responses in various diseases and disorders, including asthma and allergic diseases, as well as autoimmune


pathologies such as rheumatoid arthritis and atherosclerosis. These small secreted molecules are a growing superfamily of 8-14 kDa proteins characterised by a conserved four cysteine motif. The chemokine superfamily can be divided into two main groups exhibiting characteristic structural motifs, the Cys-X-Cys (C-X-C, or α) and Cys-Cys (C-C, or β) families. These are distinguished on the basis of a single amino acid insertion
 5 between the NH-proximal pair of cysteine residues and sequence similarity.

The C-X-C chemokines include several potent chemoattractants and activators of neutrophils such as interleukin-8 (IL-8) and neutrophil-activating peptide 2 (NAP-2).

The C-C chemokines include potent chemoattractants of monocytes and
 10 lymphocytes but not neutrophils such as human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2 and MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), eotaxin and the macrophage inflammatory proteins 1 α and 1 β (MIP-1 α and MIP-1 β).

Studies have demonstrated that the actions of the chemokines are mediated by
 15 subfamilies of G protein-coupled receptors, among which are the receptors designated CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CXCR1, CXCR2, CXCR3 and CXCR4. These receptors represent good targets for drug development since agents which modulate these receptors would be useful in the treatment of disorders and diseases such as those mentioned above.

20 The present invention provides a compound of formula (I):



wherein:

X is CH₂, C(O), O, S, S(O), S(O)₂ or NR³;

Y is a bond, C₁₋₆ alkylene (optionally substituted by C₁₋₄ alkyl or phenyl), phenylene
 25 (optionally substituted by halogen, hydroxy, C₁₋₄ alkyl or C₁₋₄ alkoxy) or heterocyclylene (optionally substituted by halogen, hydroxy, C₁₋₄ alkyl or C₁₋₄ alkoxy);

Z is CO₂R^b, NHS(O)₂CF₃, S(O)₂OH, OCH₂CO₂R^b or tetrazolyl;

R¹ is hydrogen, C₁₋₆ alkyl, aryl or heterocyclyl;

R² is hydrogen, C₁₋₆ alkyl, aryl or heterocyclyl;

R^a and R^b are, independently, hydrogen or C_{1-4} alkyl; or when R^2 is aryl or heterocyclyl R^a may be C_{2-3} alkylene forming a ring with an ortho position on R^2 ;

R^c is hydrogen or hydroxy;

wherein, unless stated otherwise, the foregoing aryl and heterocyclyl moieties are

- 5 optionally substituted by: halogen, cyano, nitro, hydroxy, oxo, $S(O)_p R^4$, $OC(O)NR^5 R^6$, $NR^7 R^8$, $NR^9 C(O)R^{10}$, $NR^{11} C(O)NR^{12} R^{13}$, $S(O)_2 NR^{14} R^{15}$, $NR^{16} S(O)_2 R^{17}$, $C(O)NR^{18} R^{19}$, $C(O)R^{20}$, $CO_2 R^{21}$, $NR^{22} CO_2 R^{23}$, C_{1-6} alkyl, CF_3 , C_{1-6} alkoxy(C_{1-6})alkyl, C_{1-6} alkoxy, OCF_3 , C_{1-6} alkoxy(C_{1-6})alkoxy, C_{1-6} alkylthio, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl (itself optionally substituted by C_{1-4} alkyl or oxo), methylenedioxy, difluoromethylenedioxy,
 - 10 phenyl, phenyl(C_{1-4})alkyl, phenoxy, phenylthio, phenyl(C_{1-4})alkoxy, heterocyclyl, heterocyclyl(C_{1-4})alkyl, heterocycliloxy or heterocyclyl(C_{1-4})alkoxy; wherein any of the immediately foregoing phenyl and heterocyclyl moieties are optionally substituted with halogen, hydroxy, nitro, $S(O)_q(C_{1-4}$ alkyl), $S(O)_2 NH_2$, $S(O)_2 NH(C_{1-4}$ alkyl), $S(O)_2 N(C_{1-4}$ alkyl)₂ (and these alkyl groups may join to form a ring as described for R^5 and R^6 below),
 - 15 cyano, C_{1-4} alkyl, C_{1-4} alkoxy, $C(O)NH_2$, $C(O)NH(C_{1-4}$ alkyl), $C(O)N(C_{1-4}$ alkyl)₂ (and these alkyl groups may join to form a ring as described for R^5 and R^6 below), $CO_2 H$, $CO_2(C_{1-4}$ alkyl), $NHC(O)(C_{1-4}$ alkyl), $NHS(O)_2(C_{1-4}$ alkyl), $C(O)(C_{1-4}$ alkyl), CF_3 or OCF_3 ;
- p and q are, independently, 0, 1 or 2;
- R^3 , R^5 , R^6 , R^7 , R^8 , R^9 , R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , R^{18} , R^{19} , R^{20} , R^{21} and R^{22} are,
- 20 independently, hydrogen, C_{1-6} alkyl (optionally substituted by halogen, hydroxy or C_{3-10} cycloalkyl), $CH_2(C_{2-6}$ alkenyl), phenyl (itself optionally substituted by halogen, hydroxy, nitro, NH_2 , $NH(C_{1-4}$ alkyl), $N(C_{1-4}$ alkyl)₂ (and these alkyl groups may join to form a ring as described for R^5 and R^6 below), $S(O)_2(C_{1-4}$ alkyl), $S(O)_2 NH_2$, $S(O)_2 NH(C_{1-4}$ alkyl), $S(O)_2 N(C_{1-4}$ alkyl)₂ (and these alkyl groups may join to form a ring as described for R^5 and
 - 25 R^6 below), cyano, C_{1-4} alkyl, C_{1-4} alkoxy, $C(O)NH_2$, $C(O)NH(C_{1-4}$ alkyl), $C(O)N(C_{1-4}$ alkyl)₂ (and these alkyl groups may join to form a ring as described for R^5 and R^6 below), $CO_2 H$, $CO_2(C_{1-4}$ alkyl), $NHC(O)(C_{1-4}$ alkyl), $NHS(O)_2(C_{1-4}$ alkyl), $C(O)(C_{1-4}$ alkyl), CF_3 or OCF_3) or heterocyclyl (itself optionally substituted by halogen, hydroxy, nitro, NH_2 , $NH(C_{1-4}$ alkyl), $N(C_{1-4}$ alkyl)₂ (and these alkyl groups may join to form a ring as described
 - 30 for R^5 and R^6 below), $S(O)_2(C_{1-4}$ alkyl), $S(O)_2 NH_2$, $S(O)_2 NH(C_{1-4}$ alkyl), $S(O)_2 N(C_{1-4}$ alkyl)₂ (and these alkyl groups may join to form a ring as described for R^5 and R^6 below), cyano, C_{1-4} alkyl, C_{1-4} alkoxy, $C(O)NH_2$, $C(O)NH(C_{1-4}$ alkyl), $C(O)N(C_{1-4}$ alkyl)₂ (and these alkyl groups may join to form a ring as described for R^5 and R^6 below), $CO_2 H$,

CO₂(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl), C(O)(C₁₋₄ alkyl), CF₃ or OCF₃);

alternatively NR⁵R⁶, NR⁷R⁸, NR¹²R¹³, NR¹⁴R¹⁵, NR¹⁸R¹⁹, may, independently, form a 4-7 membered heterocyclic ring, azetidine, pyrrolidine, piperidine, azepine, morpholine or

5 piperazine, the latter optionally substituted by C₁₋₄ alkyl on the distal nitrogen;

R⁴, R¹⁷ and R²³ are, independently, C₁₋₆ alkyl (optionally substituted by halogen, hydroxy or C₃₋₁₀ cycloalkyl), CH₂(C₂₋₆ alkenyl), phenyl (itself optionally substituted by halogen, hydroxy, nitro, NH₂, NH(C₁₋₄ alkyl), N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁵ and R⁶ above), S(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl),

10 S(O)₂N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁵ and R⁶ above), cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, C(O)NH₂, C(O)NH(C₁₋₄ alkyl),

C(O)N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁵ and R⁶ above), CO₂H, CO₂(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl), C(O)(C₁₋₄ alkyl), CF₃ or OCF₃) or heterocyclyl (itself optionally substituted by halogen, hydroxy,

15 nitro, NH₂, NH(C₁₋₄ alkyl), N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁵ and R⁶ above), S(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl),

S(O)₂N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁵ and R⁶ above), cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, C(O)NH₂, C(O)NH(C₁₋₄ alkyl), C(O)N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁵ and R⁶ above),

20 CO₂H, CO₂(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl), C(O)(C₁₋₄ alkyl), CF₃ or OCF₃);

or an N-oxide thereof; or a pharmaceutically acceptable salt thereof; or a solvate thereof.

Certain compounds of the present invention can exist in different isomeric forms (such as enantiomers, diastereomers, geometric isomers or tautomers). The present

25 invention covers all such isomers and mixtures thereof in all proportions.

Suitable salts include acid addition salts such as a hydrochloride, dihydrochloride, hydrobromide, sulfate, phosphate, acetate, diacetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulfonate, ethanesulfonate or *p*-toluenesulfonate. Salts also include metal salts, such as an alkali metal salt (for example a sodium or potassium salt) or an alkaline

30 earth metal salt (for example magnesium or calcium).

The compounds of the invention may exist as solvates (such as hydrates) and the present invention covers all such solvates.

Halogen includes fluorine, chlorine, bromine and iodine. Halogen is, for example, fluorine or chlorine.

Alkyl groups and moieties are straight or branched chain and comprise, for example, 1 to 6 (such as 1 to 4) carbon atoms. Examples of alkyl groups are methyl, ethyl, 5 n-propyl, iso-propyl or tert-butyl.

Alkylene is a straight carbon chain of 1 to 6 carbons, which is optionally substituted. Alkylene includes CH₂ or CH₂CH₂, and when substituted by alkyl (for example) it can be CH(CH₃) or CH₂C(CH₃)₂.

Alkenyl groups comprise, for example, 2 to 6 (such as 2 to 4) carbon atoms. 10 Examples of alkenyl groups are vinyl or allyl.

Alkynyl groups comprise, for example, 2 to 6 (such as 2 to 4) carbon atoms. An example of an alkynyl group is propargyl.

In one embodiment cycloalkyl groups comprise from 3 to 10 (such as 3 to 8, for example 3 to 6) carbon atoms and are mono-, bi or tricyclic. Cycloalkyl is, for example, 15 cyclopropyl, cyclopentyl, cyclohexyl, norbornyl or camphoryl. The cycloalkyl ring is optionally fused to a benzene ring (for example forming a bicyclo[4.2.0]octa-1,3,5-trienyl or indanyl ring system).

In another embodiment cycloalkenyl comprises from 3 to 8 (such as from 3 to 6) carbon atoms and is, for example, monocyclic. Cycloalkenyl is, for example, 20 cyclopentenyl or cyclohexenyl.

Aryl includes phenyl or naphthyl.

Heterocyclyl is an aromatic or non-aromatic 5 or 6 membered ring, optionally fused to one or more other rings, comprising at least one heteroatom selected from the group comprising nitrogen, oxygen and sulfur; or an N-oxide thereof, or an S-oxide or S-dioxide thereof. Heterocyclyl is, for example, furyl, thienyl (also known as thiophenyl), pyrrolyl, 25 2,5-dihydropyrrolyl, thiazolyl, pyrazolyl, oxazolyl, isoxazolyl, imidazolyl, piperidinyl, morpholinyl, pyridinyl, dihydropyridinyl (for example in a 6-oxo-1,6-dihydro-pyridinyl moiety), pyrimidinyl, indolyl, 2,3-dihydroindolyl, benzo[b]furyl (also known as benzfuryl), benz[b]thienyl (also known as benzthienyl or benzthiophenyl), 2,3-dihydrobenz[b]thienyl (for example in a 1-dioxo-2,3-dihydrobenz[b]thienyl moiety), indazolyl, benzimidazolyl, 30 benztriazolyl, benzoxazolyl, benzthiazolyl (for example in a 1H-benzthiazol-2-one-yl moiety), 2,3-dihydrobenzthiazolyl (for example in a 2,3-dihydrobenzthiazol-2-one-yl moiety), 1,2,3-benzothiadiazolyl, an imidazopyridinyl (such as imidazo[1,2a]pyridinyl),

thieno[3,2-b]pyridin-6-yl 1,2,3-benzoxadiazolyl (also known as benzo[1,2,3]thiadiazolyl),
 2,1,3-benzothiadiazolyl, benzofurazan (also known as 2,1,3-benzoxadiazolyl),
 quinoxaliny, dihydro-1-benzopyryliumyl (for example in a coumariny or a chromonyl
 moiety), 3,4-dihydro-1H-2,1-benzothiazinyl (for example in a 2-dioxo-3,4-dihydro-1H-
 5 2,1-benzothiazinyl moiety), a pyrazolopyridine (for example 1H-pyrazolo[3,4-b]pyridinyl),
 a purine (for example in a 3,7-dihydro-purin-2,6-dione-8-yl moiety), quinoliny,
 isoquinoliny, dihydroisoquinoliny (for example in a 2H-isoquinolin-1-one-yl moiety), a
 naphthyridiny (for example [1,6]naphthyridiny or [1,8]naphthyridiny), a
 dihydro[1,8]naphthyridiny (for example in a 1H-[1,8]naphthyridin-4-one-yl moiety), a
 10 benzothiazinyl, a dihydrobenzothiazinyl (for example in a 4H-benzo[1,4]thiazin-3-one-yl
 moiety), benzo[d]imidazo[2,1-b]thiazol-2-yl or dibenzothiophenyl (also known as
 dibenzothiényl); or an N-oxide thereof, or an S-oxide or S-dioxide thereof.

An N-oxide of a compound of formula (I) is, for example, a 1-oxy-
 [1,4']bipiperidiny-1'-yl compound.

15 Phenylene is a phenyl ring joining the carbon to which, *inter alia*, R² is attached,
 and the group Z (such as in Example 42 below).

Heterocyclylene is a heterocyclyl ring joining the carbon to which, *inter alia*, R² is
 attached, and the group Z (such as in Example 48 below). Heterocyclylene is, for example,
 pyridyl or oxazolyl.

20 When R² is aryl or heterocyclyl and R^a is C₂₋₃ alkylene which forms a ring with an
 ortho position on R² the resulting compound comprises, for example, an indene ring
 system. (See, for example, Example 41.)


Phenyl(C₁₋₄ alkyl) is, for example, benzyl or 2-phenyleth-1-yl.

Phenyl(C₁₋₄ alkoxy) is, for example, benzyloxy or 2-phenyleth-1-yloxy.

25 Heterocyclyl(C₁₋₄ alkyl) is, for example, pyridylmethyl or 2-pyridyleth-1-yl.

Heterocyclyl(C₁₋₄ alkoxy) is, for example, pyridyloxy or 2-pyridyleth-1-yloxy.

In one particular aspect the invention provides a compound of formula (Ia):



wherein:

X is CH₂, C(O), O, S, S(O), S(O)₂ or NR³;

Y is a bond, C₁₋₆ alkylene (optionally substituted by C₁₋₄ alkyl or phenyl) or phenylene (optionally substituted by halogen, hydroxy, C₁₋₄ alkyl or C₁₋₄ alkoxy);

R^a and R^b are, independently, hydrogen or C₁₋₄ alkyl;

5 R^c is hydrogen or hydroxy;

R¹ is hydrogen, C₁₋₆ alkyl, aryl or heterocyclyl;

R² is hydrogen, C₁₋₆ alkyl, aryl or heterocyclyl;

wherein, unless stated otherwise, the foregoing aryl and heterocyclyl moieties are

optionally substituted by: halogen, cyano, nitro, hydroxy, oxo, S(O)_pR⁴, OC(O)NR⁵R⁶,
 10 NR⁷R⁸, NR⁹C(O)R¹⁰, NR¹¹C(O)NR¹²R¹³, S(O)₂NR¹⁴R¹⁵, NR¹⁶S(O)₂R¹⁷, C(O)NR¹⁸R¹⁹,
 C(O)R²⁰, CO₂R²¹, NR²²CO₂R²³, C₁₋₆ alkyl, CF₃, C₁₋₆ alkoxy(C₁₋₆)alkyl, C₁₋₆ alkoxy, OCF₃,
 C₁₋₆ alkoxy(C₁₋₆)alkoxy, C₁₋₆ alkylthio, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl (itself
 optionally substituted by C₁₋₄ alkyl or oxo), methylenedioxy, difluoromethylenedioxy,
 phenyl, phenyl(C₁₋₄)alkyl, phenoxy, phenylthio, phenyl(C₁₋₄)alkoxy, heterocyclyl,
 15 heterocyclyl(C₁₋₄)alkyl, heterocycliloxy or heterocyclyl(C₁₋₄)alkoxy; wherein any of the
 immediately foregoing phenyl and heterocyclyl moieties are optionally substituted with
 halogen, hydroxy, nitro, S(O)_q(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl), S(O)₂N(C₁₋₄
 alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁵ and R⁶ below),
 cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, C(O)NH₂, C(O)NH(C₁₋₄ alkyl), C(O)N(C₁₋₄ alkyl)₂ (and
 20 these alkyl groups may join to form a ring as described for R⁵ and R⁶ below), CO₂H,
 CO₂(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl), C(O)(C₁₋₄ alkyl), CF₃ or OCF₃;
 p and q are, independently, 0, 1 or 2;

R³, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁸, R¹⁹, R²⁰, R²¹ and R²² are,
 independently, hydrogen, C₁₋₆ alkyl (optionally substituted by halogen, hydroxy or C₃₋₁₀
 25 cycloalkyl), CH₂(C₂₋₆ alkenyl), phenyl (itself optionally substituted by halogen, hydroxy,
 nitro, NH₂, NH(C₁₋₄ alkyl), N(C₁₋₄ alkyl)₂, S(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄
 alkyl), S(O)₂N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for
 R⁵ and R⁶ below), cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, C(O)NH₂, C(O)NH(C₁₋₄ alkyl),
 C(O)N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁵ and
 30 R⁶ below), CO₂H, CO₂(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl), C(O)(C₁₋₄
 alkyl), CF₃ or OCF₃) or heterocyclyl (itself optionally substituted by halogen, hydroxy,
 nitro, NH₂, NH(C₁₋₄ alkyl), N(C₁₋₄ alkyl)₂, S(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄
 alkyl), S(O)₂N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for

- R⁵ and R⁶ below), cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, C(O)NH₂, C(O)NH(C₁₋₄ alkyl), C(O)N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁵ and R⁶ below), CO₂H, CO₂(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl), C(O)(C₁₋₄ alkyl), CF₃ or OCF₃);
- 5 alternatively NR⁵R⁶, NR⁷R⁸, NR¹²R¹³, NR¹⁴R¹⁵, NR¹⁸R¹⁹, may, independently, form a 4-7 membered heterocyclic ring, azetidine, pyrrolidine, piperidine, azepine, morpholine or piperazine, the latter optionally substituted by C₁₋₄ alkyl on the distal nitrogen;
- R⁴, R¹⁷ and R²³ are, independently, C₁₋₆ alkyl (optionally substituted by halogen, hydroxy or C₃₋₁₀ cycloalkyl), CH₂(C₂₋₆ alkenyl), phenyl (itself optionally substituted by halogen, hydroxy, nitro, NH₂, NH(C₁₋₄ alkyl), N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁵ and R⁶ above), S(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl), S(O)₂N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁵ and R⁶ above), cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, C(O)NH₂, C(O)NH(C₁₋₄ alkyl), C(O)N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁵ and R⁶ above), CO₂H, CO₂(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl), C(O)(C₁₋₄ alkyl), CF₃ or OCF₃) or heterocyclyl (itself optionally substituted by halogen, hydroxy, nitro, NH₂, NH(C₁₋₄ alkyl), N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁵ and R⁶ above), S(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl), S(O)₂N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁵ and R⁶ above), cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, C(O)NH₂, C(O)NH(C₁₋₄ alkyl), C(O)N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁵ and R⁶ above), CO₂H, CO₂(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl), C(O)(C₁₋₄ alkyl), CF₃ or OCF₃);
- 10 or an N-oxide thereof; or a pharmaceutically acceptable salt thereof; or a solvate thereof.

25 In another aspect the invention provides a compound wherein X is O.

In yet another aspect R¹ is phenyl optionally substituted (for example independently mono- or di-substituted) with halogen (for example chlorine or fluorine), C₁₋₄ alkyl (for example methyl) or C₁₋₄ alkoxy (for example methoxy).

In a further aspect R¹ is phenyl optionally substituted (for example with one, two or three of the same or different) with fluorine, chlorine, C₁₋₄ alkyl (for example methyl) or C₁₋₄ alkoxy (for example methoxy). In a still further aspect R¹ is phenyl substituted by one, two or three (for example two or three) substituents independently selected from: fluorine, chlorine and methyl. For example R¹ is 3,4-dichlorophenyl, 2,4-dichloro-3-

30

methylphenyl, 3,4-dichloro-2-methylphenyl, 2,4-dichlorophenyl, 4-chloro-2-methylphenyl or 2-chloro-4-fluorophenyl.

In another aspect R^a is hydrogen.

In another aspect R^b is hydrogen or methyl.

5 In another aspect R^c is hydrogen.

In a further aspect R^2 is unsubstituted phenyl or naphthyl, mono-, di- or tri-substituted phenyl or naphthyl or mono-substituted heterocyclyl, the substituents being chosen from those described above.

10 Heterocyclyl is, for example, pyrimidinyl or pyridinyl. In a further aspect of the invention heterocyclyl is optionally substituted by C_{1-4} alkyl or C_{1-4} alkoxy.

In another aspect R^2 is hydrogen or phenyl optionally substituted by: halogen (for example fluoro), C_{1-6} alkyl, C_{1-6} alkoxy or $(C_{1-6} \text{ alkyl})C(O)NH$.

15 In a further aspect the present invention provides a compound of formula (I) wherein X is O; R^1 is phenyl optionally substituted by halogen (for example chlorine) or C_{1-4} alkyl (for example methyl); and R^a , R^b , R^c and R^2 is as defined above.


20 In a still further aspect the present invention provides a compound wherein Y is a bond or alkylene (optionally substituted by C_{1-4} alkyl); R^a is hydrogen; and, R^2 is hydrogen, C_{1-6} alkyl, phenyl (optionally substituted by halogen, C_{1-4} alkyl, C_{1-4} alkoxy or $NHC(O)(C_{1-4} \text{ alkyl})$) or heterocyclyl (optionally substituted by halogen, C_{1-4} alkyl or C_{1-4} alkoxy).

In another aspect the present invention provides a compound wherein Y is phenylene (optionally substituted by halogen, C_{1-4} alkyl or C_{1-4} alkoxy) or heterocyclylene (optionally substituted by halogen, C_{1-4} alkyl or C_{1-4} alkoxy); R^a is hydrogen; and R^2 is hydrogen or C_{1-4} alkyl.


25 When Z is tetrazolyl it is, for example, tetrazol-5-yl. In yet another aspect of the invention Z is CO_2R^b , wherein R^b is hydrogen or C_{1-4} alkyl (for example methyl).

30 The compounds of the invention can be prepared by adaptation of methods known in the art, by adaptation of the Examples given below or by using or adapting the methods in Scheme 1 (in which EDCI is ethyl dimethylaminopropyl carbodiimide; HOBT is 1-hydroxybenzotriazole hydrate; and DMAP is *N,N*-dimethylaminopyridine).

A compound of formula (I), for example wherein R^a is hydrogen and Z is CO_2R^b , can be prepared by coupling a compound of formula (II):




with a compound of formula (III):




wherein L is a suitable leaving group (such as halogen (such as chloro or bromo), C₁₋₆ alkylsulfonyl (such as mesylate) or tosylate) and the coupling can be carried out in a suitable solvent (such as water or N,N-dimethylformamide) at ambient temperature.

Alternatively, a compound of formula (I), wherein R^a is hydrogen and Z is CO₂R^b, can be prepared by reductive amination of a compound (II) with a compound of formula (IV):




wherein R^b is C₁₋₄ alkyl, in the presence of NaBH(OAc)₃ and acetic acid, or NaBH₃CN in a suitable solvent (such as tetrahydrofuran), optionally followed by hydrolysis of the ester group.

Alternatively, a compound of formula (I), wherein Y is a bond, R^a and R^b are both hydrogen and Z is CO₂H, can be prepared by a three component coupling of a compound of formula (II) with compounds of formula (V) and (VI):




in a suitable solvent (such as a C₁₋₆ aliphatic alcohol (for example ethanol)) at a suitable elevated temperature (for example reflux; such as 60-100°C).

A compound of formula (II) can be prepared by deprotecting a compound of formula (VII):




for example using trifluoroacetic acid in a suitable solvent (such as dichloromethane) or using a source of hydrogen chloride in a suitable solvent (such as dioxane).

A compound of formula (VII), wherein R^c is hydrogen, can be prepared by reacting a compound of formula (VIII):




with a compound of formula (IX):



5

in the presence of $\text{NaBH}(\text{OAc})_3$ and acetic acid, in a suitable solvent (such as tetrahydrofuran or dichloromethane).


A compound of formula (VII), wherein R^c is hydroxy, can be prepared by reacting a compound of formula (VIII) with a compound of formula (X):



10

in a suitable solvent (such as a C_{1-6} aliphatic alcohol, for example ethanol) at room temperature.

A compound of formula (I), wherein Y is a bond and Z is CO_2H , can be prepared by performing a nitrile hydrolysis on a compound of formula (XI):




15

Such a hydrolysis can be carried out by refluxing a mixture of hydrochloric acid and ethanol; or by adding MeSO_3H , water and hydrochloric acid and then refluxing the mixture.

20 A compound of formula (XI) can be used to form a compound of formula (I) wherein Z is tetrazol-5-yl by reacting it with $(\text{CH}_3)_3\text{SiN}_3$ and $(\text{Bu}_3\text{Sn})_2\text{O}$ at an elevated temperature (for example in toluene at reflux).

A compound of formula (XI) can be reduced to form a compound of formula (XII):



using sodium borohydride and cobalt (II) chloride in methanol. A compound of formula (XII) can then be reacted with triflic anhydride at a reduced temperature (for example -78°C in dichloromethane) to form the corresponding compound where Z is NHS(O)₂CF₃.

- 5 A compound of formula (XI) can be prepared by reacting a compound of formula (II) with R^aR²C(O) and titanium isopropoxide (Ti(OiPr)₄), followed by Et₂AlCN. Longer chain variants of the compound of formula (XI) can be made by reacting a compound of formula (II) with: a compound Hal-(CH₂)_nCN in the presence of a base (such as potassium carbonate) in acetone; or CH₂=CH-CN in the presence of a base (such as potassium carbonate) in acetone; wherein Hal is chlorine, bromine or iodine.
- 10

The preparation of various intermediates can be found in WO00/66559 and WO01/77101; alternatively they can be prepared by using or adapting literature methods.

- Compounds of formula (III) to (IX) can be prepared by using or adapting methods described in the art. The preparation of various phenoxy piperidines is described in WO
- 15 01/77101.

A compound of formula (I), wherein Y is CHR^d; R^d is hydrogen, C₁₋₄ alkyl or phenyl; and Z is CO₂R^b, can be prepared by reacting a compound of formula (II) with an alkene of formula R²R^aC=CHR^dCO₂R^b in a suitable solvent, such as ethanol, at a suitable elevated temperature, such as 50-100°C.

- 20 A compound of formula (I), wherein R^a is hydrogen, Y is CH₂ and Z is CO₂R^b, can be prepared by reacting a compound of formula (II) with an alkyne of formula R²C≡CCO₂R^b in a suitable solvent, such as ethanol, at a suitable elevated temperature, such as 50-100°C; and then reducing the alkene product so formed (for example by catalytic hydrogenation).

- 25 A compound of formula (I), wherein R² and R^a are hydrogen, Y is phenylene (optionally substituted by halogen, hydroxy, C₁₋₄ alkyl or C₁₋₄ alkoxy) and Z is CO₂R^b, can be prepared by reacting a compound of formula (II) with a benzyl bromide of formula BrCH₂-Y-CO₂R^b in the presence of diisopropylethylamine (DIPEA), in a suitable solvent (such as acetonitrile) and at ambient temperature (such as in the range 10-30°C).

Alternatively, a compound of formula (I), wherein R^2 and R^a are hydrogen, Y is phenylene (optionally substituted by halogen, hydroxy, C_{1-4} alkyl or C_{1-4} alkoxy) and Z is CO_2R^b , can be prepared by reacting a compound of formula (II) with a benzaldehyde of formula $(O)HC-Y-CO_2R^b$ wherein R^b is C_{1-4} alkyl, in the presence of $NaBH(OAc)_3$ and
5 acetic acid, in a suitable solvent (such as tetrahydrofuran), optionally followed by hydrolysis of the ester group.

Compounds of formula (I) wherein R^2 , and R^a are both hydrogen; Y is CH_2 ; and Z is CO_2R^b can be prepared by a Michael addition of $CH_2=CH-CO_2R^b$ on a compound of formula (II).

10 In another aspect the present invention provides processes for the preparation of compounds of formula (I) or (Ia).

The compounds of the invention have activity as pharmaceuticals, in particular as modulators of chemokine receptor (such as CCR3) activity, and may be used in the treatment of autoimmune, inflammatory, proliferative or hyperproliferative diseases, or
15 immunologically-mediated diseases (including rejection of transplanted organs or tissues and Acquired Immunodeficiency Syndrome (AIDS)).

Examples of these conditions are:

- (1) (the respiratory tract) obstructive diseases of airways including: chronic obstructive pulmonary disease (COPD) (such as irreversible COPD); asthma (such as bronchial,
20 allergic, intrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma (for example late asthma or airways hyper-responsiveness)); bronchitis (such as eosinophilic bronchitis); acute, allergic, atrophic rhinitis or chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous or
25 pseudomembranous rhinitis or scrofulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) or vasomotor rhinitis; sarcoidosis; farmer's lung and related diseases; nasal polyposis; fibroid lung, idiopathic interstitial pneumonia, antitussive activity, treatment of chronic cough associated with inflammatory conditions of the airways or iatrogenic induced cough;
- 30 (2) (bone and joints) arthrides including rheumatic, infectious, autoimmune, seronegative spondyloarthropathies (such as ankylosing spondylitis, psoriatic arthritis or Reiter's disease), Behçet's disease, Sjogren's syndrome or systemic sclerosis;

- (3) (skin and eyes) psoriasis, atopic dermatitis, contact dermatitis or other eczematous dermatides, seborrhoetic dermatitis, lichen planus, pemphigus, bullous pemphigus, epidermolysis bullosa, urticaria, angiodermas, vasculitides erythemas, cutaneous eosinophilias, uveitis, alopecia areata, corneal ulcer or vernal conjunctivitis;
- 5 (4) (gastrointestinal tract) Coeliac disease, proctitis, eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, irritable bowel disease or food-related allergies which have effects remote from the gut (for example migraine, rhinitis or eczema);
- 10 (5) (Allograft rejection) acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin or cornea; or chronic graft versus host disease; and/or
- 15 (6) (other tissues or diseases) Alzheimer's disease, multiple sclerosis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), lupus disorders (such as lupus erythematosus or systemic lupus), erythematosus, Hashimoto's thyroiditis, myasthenia gravis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, leprosy (such as lepromatous leprosy), periodontal disease, Sezary syndrome, idiopathic thrombocytopenia pupura or disorders of the menstrual cycle.

The compounds of formula (I) or (Ia) or a pharmaceutically acceptable salt thereof or a solvate thereof, are also H1 antagonists (and can, therefore, be used in the treatment of
20 allergic disorders); and may also be used to control a sign and/or symptom of what is commonly referred to as a cold (for example a sign and/or symptom of a common cold or influenza or other associated respiratory virus infection).

According to a further feature of the present invention there is provided a method for treating a chemokine mediated disease state (such as a CCR3 mediated disease state) in
25 a mammal, such as man, suffering from, or at risk of, said disease state, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound of the formula (I) or (Ia) or a pharmaceutically acceptable salt thereof or a solvate thereof.

According to another feature of the present invention there is provided a method for
30 antagonising H1 in a mammal, such as man, suffering from, or at risk of, an H1 mediated disease state, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound of the formula (I) or (Ia) or a pharmaceutically acceptable salt thereof or a solvate thereof.

According to yet another feature of the present invention there is provided a method for treating a sign and/or symptom of what is commonly referred to as a cold in a mammal, such as man, suffering from, or at risk of, said disease state, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound of the formula (I) or (Ia) or a pharmaceutically acceptable salt thereof or a solvate thereof.

The invention also provides a compound of the formula (I) or (Ia), or a pharmaceutically acceptable salt thereof or a solvate thereof, for use in therapy.

In another aspect the invention provides the use of a compound of formula (I) or (Ia), or a pharmaceutically acceptable salt thereof or a solvate thereof, in the manufacture of a medicament for use in therapy (for example modulating chemokine receptor activity (such as CCR3 receptor activity), antagonising H1 or treating a sign and/or symptom of what is commonly referred to as a cold).

The invention further provides the use of a compound of formula (I) or (Ia), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of:

- (1) (the respiratory tract) obstructive diseases of airways including: chronic obstructive pulmonary disease (COPD) (such as irreversible COPD); asthma {such as bronchial, allergic, intrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma (for example late asthma or airways hyper-responsiveness)}; bronchitis {such as eosinophilic bronchitis}; acute, allergic, atrophic rhinitis or chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous or pseudomembranous rhinitis or scrofulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) or vasomotor rhinitis; sarcoidosis; farmer's lung and related diseases; nasal polyposis; fibroid lung, idiopathic interstitial pneumonia, antitussive activity, treatment of chronic cough associated with inflammatory conditions of the airways or iatrogenic induced cough;
- (2) (bone and joints) arthrides including rheumatic, infectious, autoimmune, seronegative spondyloarthropathies (such as ankylosing spondylitis, psoriatic arthritis or Reiter's disease), Behcet's disease, Sjogren's syndrome or systemic sclerosis;
- (3) (skin and eyes) psoriasis, atopic dermatitis, contact dermatitis or other eczematous dermatides, seborrhoetic dermatitis, lichen planus, pemphigus, bullous pemphigus,

- epidermolysis bullosa, urticaria, angiodermas, vasculitides erythemas, cutaneous eosinophilias, uveitis, alopecia areata, corneal ulcer or vernal conjunctivitis;
- (4) (gastrointestinal tract) Coeliac disease, proctitis, eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, irritable bowel disease or food-related allergies which have effects remote from the gut (for example migraine, rhinitis or eczema);
- (5) (Allograft rejection) acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin or cornea; or chronic graft versus host disease; and/or
- (6) (other tissues or diseases) Alzheimer's disease, multiple sclerosis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), lupus disorders (such as lupus erythematosus or systemic lupus), erythematosus, Hashimoto's thyroiditis, myasthenia gravis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, leprosy (such as lepromatous leprosy), Peridontal disease, sezary syndrome, idiopathic thrombocytopenia pupura or disorders of the menstrual cycle;
- in a mammal (for example man).

In a further aspect the invention provides a compound of formula (I) or (Ia), or a pharmaceutically acceptable salt thereof, for use in the treatment of asthma {such as bronchial, allergic, intrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma (for example late asthma or airways hyper-responsiveness)); or rhinitis {including acute, allergic, atrophic or chronic rhinitis, such as rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous or pseudomembranous rhinitis or scrofulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) or vasomotor rhinitis}.

In a still further aspect a compound of formula (I) or (Ia), or a pharmaceutically acceptable salt thereof, is useful in the treatment of asthma.

The present invention also provides a the use of a compound of formula (I) or (Ia), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of asthma {such as bronchial, allergic, intrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma (for example late asthma or airways hyper-responsiveness)); or rhinitis {including acute, allergic, atrophic or chronic rhinitis, such as rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous or pseudomembranous

rhinitis or scrofulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) or vasomotor rhinitis}.

In order to use a compound of the invention, or a pharmaceutically acceptable salt thereof or solvate thereof, for the therapeutic treatment of a mammal, such as man, said
5 ingredient is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition. Therefore in another aspect the present invention provides a pharmaceutical composition which comprises a compound of the formula (I) or (Ia), or a pharmaceutically acceptable salt thereof or a solvate thereof (active ingredient), and a pharmaceutically acceptable adjuvant, diluent or carrier.

10 In a further aspect the present invention provides a process for the preparation of said composition which comprises mixing active ingredient with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will, for example, comprise from 0.05 to 99 %w (per cent by weight), such as from 0.05 to 80 %w, for example from 0.10 to 70 %w, such as from 0.10
15 to 50 %w, of active ingredient, all percentages by weight being based on total composition.

The pharmaceutical compositions of this invention may be administered in standard manner for the disease condition that it is desired to treat, for example by topical (such as to the lung and/or airways or to the skin), oral, rectal or parenteral administration. For
20 these purposes the compounds of this invention may be formulated by means known in the art. A suitable pharmaceutical composition of this invention is one suitable for oral administration in unit dosage form, for example a tablet or capsule which contains between 0.1 mg and 1 g of active ingredient.

Each patient may receive, for example, a dose of 0.01 mg kg^{-1} to 100 mg kg^{-1} , such as in the range of 0.1 mg kg^{-1} to 20 mg kg^{-1} , of the active ingredient administered, for
25 example, 1 to 4 times per day.

The invention will now be illustrated by the following non-limiting examples in which, unless stated otherwise:

- 30 (i) when given, ^1H NMR data is quoted and is in the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 300MHz or 400MHz using perdeuterio DMSO- D_6 (CD_3SOCD_3) or CDCl_3 as the solvent unless otherwise stated;
- (ii) mass spectra (MS) were run with an electron energy of 70 electron volts in the chemical ionisation (CI) mode using a direct exposure probe; where indicated ionisation

was effected by electron impact (EI) or fast atom bombardment (FAB); where values for m/z are given, generally only ions which indicate the parent mass are reported, and unless otherwise stated the mass ion quoted is the positive mass ion - $(M+H)^+$;

- (iii) the title and sub-title compounds of the examples and methods were named using the index name program from Advanced Chemistry Development Inc;
- (iv) unless stated otherwise, reverse phase HPLC was conducted using a Symmetry™, NovaPak™ or Xerra™ reverse phase silica column; and
- (v) the following abbreviations are used:

Boc or BOC	tert-butoxycarbonyl
HPLC	high pressure liquid chromatography
DIPEA	Diisopropylethylamine
NMP	N-methylpyrrolidone

DMSO	dimethylsulfoxide
aq	aqueous
THF	tetrahydrofuran
MeCN	acetonitrile

10

INTERMEDIATE 1

4-(3,4-Dichlorophenoxy)-1-(4-piperidinylmethyl)-piperidine

a) 1,1-Dimethylethyl 4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinecarboxylate

- 15 4-(3,4-Dichlorophenoxy)piperidine (1.27 g) was dissolved in THF (20 mL); acetic acid (0.5 mL) and 1,1-dimethylethyl 4-formyl-1-piperidinecarboxylate (1.43 g) were added to the solution. The reaction mixture was stirred at room temperature for 30 min then sodium triacetoxyborohydride (1.53 g) was added and the mixture was stirred at room temperature overnight. The reaction mixture was poured into 2M sodium hydroxide
- 20 solution (50 mL) and product was extracted with ether. The ether was washed with brine, dried, filtered and evaporated. Crude material was purified by flash chromatography (eluting with 979 : 20 : 1 dichloromethane : methanol : aqueous ammonia) to give the subtitle compound (2.15 g).

MS 443/445 $[M+H]^+$ (ES+)

- 25 $^1\text{H NMR } \delta_{(\text{CDCl}_3)}$ 1.06 (2H, ddd), 1.45 (9H, s), 1.61 - 1.82 (5H, m), 1.92 - 1.98 (2H, m), 2.16 - 2.27 (4H, m), 2.65 - 2.73 (4H, m), 4.08 (2H, d), 4.25 (1H, dq), 6.75 (1H, dd), 6.99 (1H, d), 7.30 (1H, d)

b) 4-(3,4-dichlorophenoxy)-1-(4-piperidinylmethyl)-piperidine

1,1-Dimethylethyl 4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinecarboxylate (1.0 g) was added to a mixture of 20% TFA in dichloromethane (20 mL) and the mixture was stirred at room temperature for 1h. Solvent was removed by

5 evaporation and 2M sodium hydroxide solution (25 mL) was added to the residue. Product was extracted with ethyl acetate. The organic phase was washed with brine, dried, filtered and evaporated to give the title compound (0.5 g).

MS 343/345 [M+H]⁺ (ES⁺)

¹H NMR δ_(CDCl₃) 1.10 (2H, qd), 1.60 (1H, qquintet), 1.73 - 1.83 (4H, m), 1.90 - 2.01
10 (2H, m), 2.16 - 2.26 (4H, m), 2.55 - 2.70 (4H, m), 3.09 (2H, d), 4.24 (1H, dqintet), 6.75 (1H, dd), 6.99 (1H, d), 7.27 (1H, d)

The following intermediates were prepared analogously from the appropriate aryloxy piperidine:

Intermediate	Name	M+H	¹ H NMR
2	4-(2,4-Dichloro-3-methylphenoxy)-1-(4-piperidinylmethyl)-piperidine	357/359	δ _(CDCl₃) 1.13 - 1.27 (2H, m), 1.57 - 1.70 (1H, m), 1.76 - 2.00 (2H, m), 2.16 - 2.32 (4H, m), 2.46 (3H, s), 2.60 - 2.99 (8H, m), 3.16 (2H, d), 4.31 (1H, quintet), 6.75 (1H, d), 7.18 (1H, d)
3	4-(4-Chloro-2-methylphenoxy)-1-(4-piperidinylmethyl)-piperidine	323/325	δ _(CDCl₃) 1.08 - 1.21 (2H, m), 1.56 - 1.68 (1H, m), 1.73 - 1.86 (4H, m), 1.90 - 1.99 (2H, m), 2.16 - 2.31 (7H, m), 2.57 - 2.69 (4H, m), 3.12 (2H, d), 4.23 - 4.31 (1H, m), 6.74 (1H, d), 7.06 (1H, dd), 7.11 (1H, d)
4	4-(2,4-Dichlorophenoxy)-1-(4-piperidinylmethyl)-piperidine	343/345	

5	4-(3,4-Dichloro-2-methylphenoxy)-1-(4-piperidinylmethyl)-piperidine	357/359	$\delta_{(\text{CD}_3\text{OD})}$ 1.10 - 1.22 (2H, m), 1.66 - 1.85 (5H, m), 1.94 - 2.04 (2H, m), 2.22 (2H, d), 2.31 (3H, s), 2.32 - 2.41 (2H, m), 2.59 - 2.72 (4H, m), 3.08 (2H, d), 4.38 - 4.46 (1H, m), 6.91 (1H, d), 7.27 (1H, d)
---	---	---------	--

INTERMEDIATE 6

4-(3-Chloro-4-fluoro-phenoxy)-piperidine

- 5 DEAD (0.43 mL) was added to a solution of triphenylphosphine (0.72 g), 3-chloro-4-fluorophenol (0.403 g) and 4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester (0.5 g) in THF at RT. The resulting mixture was stirred overnight, HCl in dioxan (2 mL of 4M) was added and the mixture stirred at RT overnight. The mixture was then evaporated to dryness and triethylamine (5 mL) was added. The mixture was evaporated and the residue
- 10 was dissolved in methanol (10 mL), placed onto a SCX cartridge (Varian, 10 g, SCX cartridge available from International Sorbent Technology Isolute® Flash SCX-2) and eluted: first with methanol then with 10%NH₃ in methanol. The basic fractions were combined and evaporated to give the product as an oil (0.6 g).

- ¹H NMR $\delta_{(\text{DMSO-}d_6)}$ 1.34 - 1.46 (2H, m), 1.83 - 1.91 (2H, m), 2.53 - 2.59 (2H, m), 2.87 - 2.96 (2H, m), 3.22 - 3.39 (1H, m), 4.39 (1H, septet), 6.92 - 6.98 (1H, m), 7.17 - 7.20 (1H, m), 7.30 (1H, t).
- 15

The following intermediate was prepared in similar manner to intermediate 6

Intermediate	name	M+H
7	4-(3,4-Dichloro-2-methylphenoxy)-piperidine	260/262

INTERMEDIATE 8

- 20 4-[[4-(3,4-Dichlorophenoxy)-1-piperidinyl]methyl]-4-piperidinol
- a) 1,1-Dimethylethyl 4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-4-hydroxy-1-piperidinecarboxylate

A solution of 4-(3,4-dichlorophenoxy)-piperidine (5.2 g) and 1,1-dimethylethyl 1-oxa-6-azaspiro[2.5]octane-6-carboxylate (4.1 g) in ethanol (50 mL) was stirred at room

temperature for 18 hours and then at 60°C for 18 hours. The solvent was evaporated to leave 9.5 g of a pale yellow oil. Flash chromatography (dichloromethane then dichloromethane : 7M ammonia in methanol 95:5) gave the subtitle compound (8.48 g).

MS $[M+H]^+$ (ES+) 459/461

5 $^1\text{H NMR } \delta_{(\text{CDCl}_3)}$ 1.35 - 1.63 (4H, m), 1.46 (9H, s), 1.73 - 1.86 (2H, m), 1.89 - 2.01 (2H, m), 2.34 (2H, s), 2.49 - 2.59 (2H, m), 2.79 - 2.89 (2H, m), 3.07 - 3.24 (2H, m), 3.79 - 3.93 (2H, m), 4.22 - 4.32 (1H, m), 6.75 (1H, dd), 6.99 (1H, d), 7.30 (1H, d)

b) 4-[[4-(3,4-Dichlorophenoxy)-1-piperidinyl]methyl]-4-piperidinol

To a solution of 1,1-dimethylethyl 4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-4-hydroxy-1-piperidinecarboxylate (5 g) in dichloromethane (50 mL) was added trifluoroacetic acid (5 mL) and the solution was stirred for 12 hours. Sodium hydroxide solution (1M) was added to give an alkaline solution, this was then extracted thrice with dichloromethane. The pooled organic phase was subsequently washed with water, dried, filtered and evaporated to give the title compound (3.5 g).

15 MS $[M+H]^+$ (ES+) 359/361

$^1\text{H NMR } \delta_{(\text{CDCl}_3)}$ 1.57 - 1.66 (4H, m), 1.69 - 1.84 (2H, m), 1.93 - 2.04 (2H, m), 2.36 (2H, s), 2.47 - 2.58 (2H, m), 2.82 - 2.92 (4H, m), 2.96 - 3.07 (2H, m), 4.32 - 4.41 (1H, m), 6.89 (1H, dd), 7.09 (1H, d), 7.38 (1H, d)

20

INTERMEDIATE 9

4-[[4-(3,4-Dichlorophenoxy)-1-piperidinyl] methyl]-1,2-cyclopentanediol

a) 4-(3,4-Dichlorophenoxy)-1-[1-oxo-2-(2-propenyl)-4-pentenyl]-piperidine

A solution of 4-(3,4-dichlorophenoxy)-piperidine (5.25 g) in dichloromethane (80 mL) was added to a solution of EDCI (2.45 g), HOBT (1.77 g) and DMAP (0.44 g) in dichloromethane (100 mL). A solution of 2-(2-propenyl)-4-pentenoic acid (1.81 g) in dichloromethane (5 mL) was added and the solution was stirred for 60 h. The reaction mixture was poured onto water. The mixture was separated and the aqueous phase was extracted twice with dichloromethane. The organic phases were washed with brine, dried, filtered and evaporated to give an oil. Chromatography of the oil (eluting dichloromethane, then 49:1 dichloromethane : methanol) gave the subtitle compound (3.40 g).

MS $[M+H]^+$ (ES+) 368/342

$^1\text{H NMR } \delta_{(\text{CDCl}_3)}$ 5.69 - 5.83 (2H, m), 5.00 - 5.11 (4H, m), 4.46 - 4.52 (1H, m), 3.62 - 3.85

(3H, m), 3.43 - 3.53 (1H, m), 2.76 - 2.87 (1H, m), 2.37 - 2.47 (2H, m), 2.17 - 2.27 (2H, m), 1.70 - 1.99 (4H, m), 6.77 (1H, dd), 7.01 (1H, d), 7.33 (1H, d)

b) 1-(3-Cyclopenten-1-ylcarbonyl)-4-(3,4-dichlorophenoxy)-piperidine

Nitrogen was bubbled through solution of 4-(3,4-dichlorophenoxy)-1-[1-oxo-2-(2-propenyl)-4-pentenyl]-piperidine (1.45 g) in dichloromethane (20 mL) for 10 min. with sonication (cleaning bath). Grubbs' catalyst (89 mg) was added and the solution was stirred for 16 h. Water was added and the phases were separated. The aqueous phase was extracted twice with dichloromethane, the organics were dried, filtered and concentrated to give the subtitle compound as a green oil (1.60 g)

10 MS $[M+H]^+$ (ES+) 340/342

^1H NMR $\delta_{(\text{CDCl}_3)}$ 4.47 - 4.53 (1H, m), 5.67 (2H, s), 7.33 (1H, d), 6.78 (1H, dd), 7.02 (1H, d), 3.62 - 3.84 (3H, m), 3.44 - 3.52 (1H, m), 3.33 (1H, d), 2.68 - 2.77 (2H, m), 2.54 - 2.64 (2H, m), 1.88 - 1.99 (2H, m), 1.73 - 1.86 (2H, m)

c) *cis* and *trans* 4-(3,4-Dichlorophenoxy)-1-[(3,4-dihydroxycyclopentyl)carbonyl]-piperidine

15 1-(3-Cyclopenten-1-ylcarbonyl)-4-(3,4-dichlorophenoxy)-piperidine (1.45 g) was dissolved in acetone (30 mL) and water (20 mL). Osmium tetroxide (1 mL of 2.5% solution in t-butanol) was added and the solution was stirred for 5 days. The reaction mixture was poured onto a solution of sodium metabisulfite. The mixture was extracted thrice with dichloromethane, the organic extracts were washed with brine, dried, filtered and evaporated to give an oil. Chromatography (eluting dichloromethane : methanol 24:1 to 37 : 3) gave the title compound as two compounds (0.31 g and 0.71 g).

MS $[M+H]^+$ (ES+) 374/376

25 Minor isomer ^1H NMR $\delta_{(\text{CDCl}_3)}$ 1.79 - 1.98 (6H, m), 2.12 - 2.22 (2H, m), 3.23 (1H, tt), 3.49 - 3.56 (1H, m), 3.65 - 3.79 (3H, m), 3.93 (1H, d), 3.99 - 4.08 (3H, m), 4.53 (1H, tt), 6.77 (1H, dd), 7.02 (1H, d), 7.34 (1H, d)

Major isomer ^1H NMR $\delta_{(\text{CDCl}_3)}$ 1.73 - 1.86 (2H, m), 1.86 - 2.00 (4H, m), 2.07 - 2.16 (2H, m), 2.50 - 2.60 (2H, m), 3.39 (1H, tt), 3.42 - 3.48 (1H, m), 3.61 - 3.78 (3H, m), 4.22 - 4.27 (2H, m), 4.47 - 4.53 (1H, m), 6.77 (1H, dd), 7.01 (1H, d), 7.33 (1H, d)

30 d) 4-[[4-(3,4-Dichlorophenoxy)-1-piperidiny]methyl]-1,2-cyclopentanediol

Borane solution (16 mL of 1M in THF) was added to 4-(3,4-dichlorophenoxy)-1-[(3,4-dihydroxycyclopentyl)carbonyl]-piperidine (major isomer, 0.71 g) and the resulting solution was heated to reflux for 90 min. Methanol (10 mL) was added and the mixture

was heated under reflux for 1 h. The solvent was removed and the residue was loaded onto an SCX2 cartridge with methanol. Washing with methanol followed by elution with 0.7M ammonia in methanol gave the title compound as a viscous oil containing solvent.

MS $[M+H]^+$ (ES+) 360/362

5

The following intermediates were prepared analogously from the appropriate aryloxy piperidine as a mixture of isomers:

Intermediate	Name	M+H	¹ H NMR
10	4-[[4-(2,4-Dichloro-3-methylphenoxy)-1-piperidinyl]methyl]-1,2-cyclopentanediol	374/376	$\delta_{(CD_3OD)}$ 1.28 - 1.37 (0.66H, m), 1.37 - 1.48 (1.34H, m), 1.69 - 1.81 (4H, m), 1.84 - 2.09 (3H, m), 2.27 (2H, d), 2.35 (3H, s), 2.36 - 2.53 (2H, m), 2.61 - 2.76 (2H, m), 3.78 - 3.85 (0.66H, m), 3.90 - 3.96 (1.34H, m), 4.32 - 4.43 (1H, m), 6.85 (1H, d), 7.16 (1H, d)
11	4-[[4-(3,4-Dichloro-2-methylphenoxy)-1-piperidinyl]methyl]-1,2-cyclopentanediol	374/376	$\delta_{(CD_3OD)}$ 1.28 - 1.36 (0.66H, m), 1.39 - 1.48 (1.34H, m), 1.68 - 1.80 (4H, m), 1.86 - 1.98 (3H, m), 2.22 (3H, s), 2.25 (2H, d), 2.29 - 2.50 (2H, m), 2.60 - 2.70 (2H, m), 3.78 - 3.84 (0.66H, m), 3.89 - 3.95 (1.34H, m), 4.29 - 4.38 (1H, m), 6.82 (1H, d), 7.18 (1H, d)

10

INTERMEDIATE 12

4-(3,4-Dichlorophenoxy)-1-(4-piperidinylmethyl)-piperidineacetonitrile

4-(3,4-Dichlorophenoxy)-1-(4-piperidinylmethyl)-piperidine (0.5 g), bromoacetonitrile (0.21 g), diisopropylethylamine (0.36 mL) and dimethylformamide (3 mL) were stirred together at room temperature, under nitro gen, for 4 hours. The mixture

was poured into water (50 mL), extracted into ethyl acetate (3 x 50 mL), washed with brine (50 mL), dried, filtered and evaporated. Flash chromatography (29:1 dichloromethane: methanol) gave the title compound as a solid (363 mg).

MS [M+H]⁺ (APCI+) 382/384

- 5 ¹H NMR $\delta_{(\text{CDCl}_3)}$ 1.24 (2H, qd), 1.45 - 1.55 (1H, m), 1.73 - 1.85 (4H, m), 1.92 - 2.00 (2H, m), 2.19 (2H, d), 2.20 - 2.27 (2H, m), 2.34 (2H, td), 2.63 - 2.71 (2H, m), 2.80 (2H, d), 3.53 (2H, s), 4.21 - 4.28 (1H, m), 6.75 (1H, dd), 6.99 (1H, d), 7.30 (1H, d)

- The following intermediates were prepared analogously from the appropriate
10 aryloxy piperidine:

Intermediate	Name	M+H	¹ H NMR
13	4-[[4-(3,4-Dichloro-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidineacetonitrile	396/398	

INTERMEDIATE 14

- 4-[[4-(3,4-Dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinepropanenitrile
4-(3,4-Dichlorophenoxy)-1-(4-piperidinylmethyl)-piperidine (0.85 g), acrylonitrile
15 (0.24 mL), diisopropylethylamine (0.72 mL) and dimethylformamide (6 mL) were stirred together at room temperature, under nitrogen, for 24 hours. The mixture was poured into water (50 mL), extracted into ethyl acetate (3 x 50 mL), washed with brine (50 mL), dried, filtered and evaporated. Flash chromatography (19:1 dichloromethane: methanol) gave the title compound as a solid (116 mg).

- 20 MS [M+H]⁺ (APCI+) 396/398

¹H NMR $\delta_{(\text{CD}_3\text{OD})}$ 1.06 - 1.23 (2H, m), 1.40 - 1.53 (1H, m), 1.60 - 1.75 (4H, m), 1.84 - 1.93 (2H, m), 1.95 - 2.06 (2H, m), 2.11 - 2.17 (2H, m), 2.17 - 2.30 (2H, m), 2.43 - 2.70 (6H, m), 2.76 - 2.95 (2H, m), 4.20 - 4.40 (1H, m), 6.78 (1H, dd), 6.99 (1H, d), 7.28 (1H, d)

25

INTERMEDIATE 15

4-[[4-(3,4-Dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidineethanamine

- 4-[[4-(3,4-Dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidineacetonitrile (0.43 g) and cobalt (II) chloride (0.3 g) in methanol (20 mL) were cooled to 5 °C, under nitrogen, and sodium borohydride (0.43 g) was added portionwise. The mixture was stirred at 5 °C for 40 minutes then poured into 2N aqueous sodium hydroxide solution (50 mL), extracted into ethyl acetate (3 x 50 mL), dried, filtered and evaporated to give the title compound (0.43 g).

¹H NMR $\delta_{(\text{CDCl}_3)}$ 1.08 - 1.28 (3H, m), 1.50 - 1.80 (6H, m), 1.88 - 2.02 (3H, m), 2.04 - 2.22 (4H, m), 2.45 (1H, s), 2.56 - 2.73 (3H, m), 2.89 (2H, m), 3.07 - 3.10 (1H, d), 4.23 (1H, m), 6.74 - 6.76 (1H, d), 6.99 (1H, s), 7.26 - 7.31 (1H, t)

The following intermediates were prepared analogously from the appropriate nitrile:

Intermediate	Name	M+H	¹ H NMR
16	4-[[4-(3,4-Dichloro-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidineethanamine		$\delta_{(\text{CDCl}_3)}$ 1.09 - 1.26 (3H, m), 1.62 - 1.85 (6H, m), 1.88 - 2.01 (3H, m), 2.16 - 2.18 (2H, d), 2.21 - 2.30 (2H, m), 2.32 (3H, s), 2.39 - 2.44 (1H, m), 2.58 - 2.71 (3H, m), 2.75 - 2.98 (2H, t), 3.03 - 3.16 (1H, d), 4.62 (1H, m), 6.70 - 6.73 (1H, d), 7.19 - 7.22 (1H, d)
17	4-[[4-(3,4-Dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinepropanamine		$\delta_{(\text{CDCl}_3)}$ 1.02 - 1.23 (2H, m), 1.40 - 1.83 (11H, m), 1.85 - 1.94 (3H, m), 2.08 - 2.20 (4H, m), 2.65 (3H, m), 2.93 - 3.20 (2H, m), 4.23 (1H, m), 6.73 - 6.76 (1H, d), 6.99 (1H, s), 7.26 - 7.31 (1H, t)

INTERMEDIATE 18

1-Methylethyl 3-formyl-2-pyridinecarboxylate

1-Methylethyl 3-(hydroxymethyl)-2-pyridinecarboxylate (1.2 g) was dissolved in dichloromethane (20 mL) and to the solution was added Dess-Martin periodinane (3.0 g).
5 The reaction mixture was stirred, under nitrogen, at room temperature, for 1 h. Sodium thiosulphate (10 g) was added to a saturated aqueous solution of sodium bicarbonate (25 mL) and this mixture was added to the reaction mixture. Ether (25 mL) was then added and the mixture was stirred rapidly for 5min. The mixture was separated, the aqueous phase was extracted with ether (2x20 mL). 2M HCl (10 mL) was added to the combined
10 ether extracts. The aqueous phase was removed, basified by careful addition of solid sodium bicarbonate and extracted with ether. This ether was dried (MgSO₄), filtered and concentrated *in vacuo* to give the title compound as a colourless oil (0.87 g).
¹H NMR δ(DMSO) 1.35 (6H, d), 5.24 (1H, quintet), 7.80 (1H, dd), 8.31 (1H, dd), 8.86 (1H, dd), 10.29 (1H, s)

15

INTERMEDIATE 19

Methyl 4-(bromomethyl)-3-fluoro- benzoate

Methyl 3-fluoro-4-methyl benzoate (0.97 g), N-bromosuccinimide (1.13 g) and azobisisobutyronitrile (0.02 g) were added to carbon tetrachloride (2 mL) and the mixture
20 was heated under reflux, whilst being irradiated with a 100W lamp, for 6h. The reaction mixture was concentrated *in vacuo* and the residue was partitioned between ethyl acetate and 1 M hydrochloric acid. The organic phase was washed with brine, dried (MgSO₄) and filtered to give a crude yellow oil which was purified by flash chromatography, eluting with 5% ethyl acetate in isohexane to give the title compound as a colourless oil (0.63 g).
25 ¹H NMR δ(CDCl₃) 3.93 (3H, s), 4.52 (2H, d), 7.47 (1H, t), 7.73 (1H, dd), 7.81 (1H, dd)

INTERMEDIATE 20

Methyl 2-(bromomethyl)-5-fluoro benzoate

Prepared following the method for Intermediate 15.

30 ¹H NMR δ(CDCl₃) 3.95 (3H, s), 4.93 (2H, s), 7.20 (1H, ddd), 7.46 (1H, dd), 7.67 (1H, dd)

INTERMEDIATE 21

Ethyl 4-[(4-hydroxy-1-piperidinyl)methyl]- α -phenyl-1-piperidineacetate

a) Ethyl 4-(hydroxymethyl)- α -phenyl-1-piperidineacetate

- 5 Ethyl α -bromobenzeneacetate (2.43 g) was dissolved in acetone (20 mL). A suspension of 4-hydroxymethylpiperidine (1.15 g) in acetone (5 mL) was added followed by potassium carbonate (2.60 g). The mixture was stirred for 16 h, filtered and concentrated to an oil. Chromatography (isohexane : ethyl acetate 1:1, then 3:7) gave the subtitle compound as an oil (2.23 g).

MS $[M+H]^+$ (ES+) 278

- 10 ^1H NMR $\delta_{(\text{CDCl}_3)}$ 1.21 (3H, t), 1.32 (1H, td), 1.41 (1H, td), 1.46 - 1.57 (1H, m), 1.63 - 1.69 (1H, m), 1.70 - 1.77 (1H, m), 1.89 (1H, td), 2.16 (1H, td), 2.76 - 2.81 (1H, m), 2.98 - 3.04 (1H, m), 3.50 (2H, d), 3.99 (1H, s), 4.09 - 4.24 (2H, m), 7.30 - 7.37 (3H, m), 7.42 - 7.46 (2H, m)

b) Ethyl 4-formyl- α -phenyl-1-piperidineacetate

- 15 DMSO (1.1 mL) was dissolved in dichloromethane (15 mL) and cooled below -60 °C. Oxalyl chloride (0.9 mL) in dichloromethane (5 mL) was added dropwise maintaining the temperature below -57°C. The solution was stirred for 15 min. then ethyl 4-(hydroxymethyl)- α -phenyl-1-piperidineacetate (2.23 g) dissolved in dichloromethane (6 mL) was added dropwise and the solution was stirred for 30 min. Triethylamine (4 mL) was added and the reaction mixture was allowed to warm to ambient temperature. Water was added, the phases were separated, the aqueous was extracted twice with dichloromethane and the organic phases were washed with brine, dried, filtered and concentrated to give the subtitle compound.

MS $[M+H]^+$ (ES+) 276

- 25 ^1H NMR $\delta_{(\text{CDCl}_3)}$ 1.21 (3H, t), 1.64 - 1.81 (2H, m), 1.82 - 1.95 (1H, m), 2.11 (1H, td), 2.19 - 2.34 (2H, m), 2.70 - 2.80 (2H, m), 2.81 - 2.90 (1H, m), 4.04 (1H, s), 4.07 - 4.25 (2H, m), 7.30 - 7.38 (3H, m), 7.39 - 7.44 (2H, m), 9.63 (1H, d)

c) Ethyl 4-[(4-hydroxy-1-piperidinyl)methyl]- α -phenyl-1-piperidineacetate

- 30 4-Hydroxypiperidine (0.81 g) and ethyl 4-formyl- α -phenyl-1-piperidineacetate (2.14 g) were suspended in THF (10 mL). Acetic acid (0.5 mL) was added followed by sodium triacetoxymethylborohydride (1.68 g) and then THF (6 mL). The suspension was stirred overnight, then sodium bicarbonate solution was added and the mixture was stirred for 5 min. The suspension was extracted thrice with ethyl acetate, the organic phases were

washed with brine, dried, filtered and evaporated. Chromatography of the residue (dichloromethane : methanol : triethylamine 90:9:1) gave the subtitle compound as an oil (2.14 g).

MS $[M+H]^+$ (ES+) 361

5 $^1\text{H NMR } \delta_{(\text{CDCl}_3)}$ 1.20 (3H, td), 1.33 (2H, qd), 1.42 - 1.49 (1H, m), 1.49 - 1.57 (2H, m), 1.69 - 1.76 (2H, m), 1.81 - 1.89 (3H, m), 2.00 - 2.12 (3H, m), 2.14 (2H, d), 2.58 - 2.78 (4H, m), 2.93 - 2.98 (1H, m), 3.61 - 3.70 (1H, m), 3.97 (1H, s), 4.07 - 4.23 (2H, m), 7.29 - 7.36 (3H, m), 7.41 - 7.45 (2H, m).

10

EXAMPLE 1

This Example illustrates the preparation of 4-[[4-(3,4-dichlorophenoxy)-1-piperidiny]methyl]- α -phenyl-1-piperidineacetic acid.

4-[[4-(3,4-Dichlorophenoxy)piperidin-1-yl]methyl]piperidine (0.5 g), and benzene boronic acid (0.2 g) were dissolved in ethanol (3 mL); glyoxylic acid (0.2 mL of a 50% solution in water) was added to the solution and the reaction mixture was heated in a microwave oven at 100°C for 5min. The resultant solution was purified by HPLC (gradient 95% - 5% aqueous ammonium acetate, 5% - 95% acetonitrile) to give the title compound (0.1 g).

MS $[M+H]^+$ (ES+) 477/479

20 $^1\text{H NMR } \delta_{(\text{CDCl}_3)}$ 1.53 - 1.77 (4H, m), 1.79 - 1.94 (4H, m), 2.14 - 2.25 (4H, m), 2.41 (1H, t), 2.54 - 2.64 (2H, m), 2.75 (1H, t), 3.38 (1H, d), 3.58 - 3.70 (2H, m), 4.15 - 4.23 (1H, m), 4.47 (1H, s), 6.71 (1H, dd), 6.96 (1H, d), 7.25 (1H, d), 7.32 - 7.38 (3H, m), 7.49 - 7.58 (2H, m).

25 Examples 2-19 (see Table I below) were made using the method of Example 1.

EXAMPLE 20

This Example illustrates the preparation of 4-[[4-(2,5-dichlorophenoxy)-1-piperidiny]methyl]- α -phenyl-1-piperidineacetic acid

30 Ethyl 4-[(4-hydroxy-1-piperidiny]methyl]- α -phenyl-1-piperidineacetate (0.135 g) was dissolved in NMP (3 mL). 1,4-Dichloro-2-fluorobenzene (0.2 mL) and potassium *t*-butoxide (56 mg) were added and the solution was heated to 50 °C for 40 h. The solution was cooled to ambient temperature and few drops of aqueous sodium hydroxide solution

were added. The mixture was stirred for 60 h, then acetic acid (few drops) was added and the solvent was distilled. The residue was purified by HPLC (0.2% aqueous ammonia : acetonitrile; gradient 95:5 to 50:50) to give the title compound (21 mg).

MS $[M+H]^+$ (ES+) 477/479

5 ^1H NMR $\delta_{(\text{CD}_3\text{OD})}$ 1.45 (1H, q), 1.68 - 1.96 (9H, m), 2.16 - 2.21 (2H, m), 2.25 - 2.34 (2H, m), 2.57 - 2.65 (3H, m), 2.80 - 2.93 (2H, m), 4.29 - 4.36 (1H, m), 4.38 - 4.44 (1H, m), 6.83 (1H, dd), 7.02 (1H, d), 7.23 (1H, d), 7.32 - 7.36 (3H, m), 7.44 - 7.49 (2H, m)

Example 21 (see Table I below) was made using the method of Example 20

10

EXAMPLE 22

This Example illustrates the preparation of methyl 4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]- α -phenyl-piperidineacetate.

15 4-(3,4-Dichlorophenoxy)-1-(4-piperidinylmethyl)-piperidine (0.30 g) and methyl- α -bromobenzeneacetate (0.22 g) were dissolved in acetone (20 mL) and potassium carbonate (0.13 g) was added. The reaction mixture was stirred at room temperature for 16 h. The suspension was filtered and the filtrate was evaporated. The residue was chromatographed eluting with ethyl acetate : methanol : triethylamine (20 : 1 : 0.001) to give the title compound (0.24 g).

20 MS $[M+H]^+$ (ES+) 491/493

^1H NMR $\delta_{(\text{CD}_3\text{OD})}$ 1.22 (1H, qd), 1.34 (2H, qd), 1.50 - 1.59 (1H, m), 1.66 (1H, d), 1.70 - 1.80 (3H, m), 1.88 (1H, td), 1.93 - 2.02 (2H, m), 2.14 (1H, td), 2.22 (2H, d), 2.25 - 2.33 (1H, m), 2.65 - 2.73 (3H, m), 2.95 - 3.01 (1H, m), 3.68 (3H, s), 3.98 (1H, s), 4.37 (1H, septet), 6.87 (1H, dd), 7.08 (1H, d), 7.31 - 7.38 (4H, m), 7.42 (2H, dd)

25

EXAMPLES 23 & 24

This Example illustrates the preparation of (*R*)-methyl 4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]- α -phenyl-piperidineacetate and (*S*)-methyl 4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]- α -phenyl-piperidineacetate.

30 Racemic methyl 4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]- α -phenyl-piperidineacetate (360 mg) was dissolved in isohexane : isopropanol (9:1) and was chromatographed on a Chiralpak AD column eluting isohexane : isopropanol (9:1) to give the 2 isomers.

First eluting isomer (50 mg); MS $[M+H]^+$ (ES+) 491/493. Retention time (chiralpak AD column (4.6 x 250 mm), maintained at 10 °C, flow rate 1 mL/min 95:5 isohexane : isopropanol containing 0.1% diethylamine) 7.2 minutes.

Second eluting isomer (30 mg); MS $[M+H]^+$ (ES+) 491/493. Retention time (chiralpak AD column (4.6 x 250 mm), maintained at 10 °C, flow rate 1 mL/min 95:5 isohexane : isopropanol containing 0.1% diethylamine) 8.9 minutes

EXAMPLE 25

This Example illustrates the preparation of (R)- 4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]- α -phenyl-piperidineacetic acid.

Methyl (R)-4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]- α -phenyl-1-piperidineacetate (45 mg) was dissolved in aq. HCl (6M, 10 mL) and heated at 80° C for 22hrs. It was dried on a rotary evaporator, redissolved in MeOH and purified by HPLC (gradient 95% - 50% aqueous ammonium acetate, 5% - 50% acetonitrile) to give the title compound (14.1 mg).

MS $[M+H]^+$ (ES+) 477/479

^1H NMR $\delta_{(\text{CD}_3\text{OD} + \text{NaOD})}$ 1.27 - 1.37 (2H, m), 1.45 - 1.62 (2H, m), 1.72 - 2.06 (8H, m), 2.31 - 2.36 (2H, m), 2.36 - 2.45 (2H, m), 2.72 - 2.80 (2H, m), 2.97 (1H, t), 4.37 - 4.46 (2H, m), 6.88 (1H, dd), 7.09 (1H, d), 7.37 (1H, d), 7.42 - 7.46 (3H, m), 7.54 - 7.58 (2H, m)

Example 26 (see Table I below) was made using the method of Example 25

EXAMPLE 27

This Example illustrates the preparation of (R)-methyl 4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]- α -phenyl-piperidineacetate

4-[[4-(3,4-Dichlorophenoxy)-1-piperidinyl]methyl]-1,2-cyclopentanediol (Intermediate 9, major isomer, 230 mg) was dissolved in dichloromethane (5 mL). Sodium carbonate (225 mg) was added and the resulting suspension was cooled in ice-water. Lead tetraacetate (310 mg) was added in small portions over 15 min. A suspension of (R)-phenylglycine methyl ester hydrochloride (129 mg) and sodium triacetoxymethylborohydride (300 mg) in THF (10 mL) was prepared in a separate flask. To this suspension was added acetic acid (50 μL) and triethylamine (100 μL) then the suspension was sonicated (cleaning bath) for 5 min. 40 min after the completion of the addition of lead tetraacetate to the diol

the resulting suspension was filtered through a plug of cotton wool into the aminoester suspension, followed by a rinse of THF (3 mL). Additional acetic acid (50 μ L) and triethylamine (100 μ L) were added to the reaction mixture which was then stirred overnight.

- 5 Aqueous sodium bicarbonate was added to the reaction mixture which was then extracted thrice with ethyl acetate. The extracts were combined, washed with brine, dried, filtered and evaporated. The residue was purified by chromatography (39:1 ethyl acetate : methanol) to give the title compound (157 mg).

MS $[M+H]^+$ (ES+) 491/493

- 10 1H NMR $\delta_{(CDCl_3)}$ 1.24 (1H, qd), 1.33 (1H, qd), 1.41 - 1.52 (1H, m), 1.70 - 1.80 (3H, m), 1.85 (1H, td), 1.90 - 1.98 (2H, m), 2.12 (1H, td), 2.16 - 2.25 (5H, m), 2.62 - 2.69 (2H, m), 2.75 (1H, d), 2.94 (1H, d), 3.69 (3H, s), 4.01 (1H, s), 4.19 - 4.26 (1H, m), 6.74 (1H, dd), 6.98 (1H, d), 7.29 (1H, d), 7.31 - 7.36 (3H, m), 7.40 - 7.44 (2H, m)

- 15 Examples 28 - 33 (see Table I below) were made using the method of Example 27

EXAMPLE 34

This Example illustrates the preparation of (*R*)- 4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]- α -phenyl-piperidineacetic acid dihydrochloride

- 20 (*R*)-Methyl 4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]- α -phenyl-piperidineacetate (150 mg) was suspended in 6M hydrochloric acid (20 mL) and heated to 80 °C for 22 h. The crystalline solid formed was collected and dried *in vacuo* to give the title compound (100 mg).

m. pt. 294-297 C

- 25 MS $[M+H]^+$ (ES+) 477/479 ppp

1H NMR $\delta_{(CD_3OD)}$ 1.43 - 1.59 (1H, m), 1.66 (1H, q), 1.86 - 2.02 (2H, m), 2.05 - 2.29 (5H, m), 2.78 - 2.93 (1H, m), 2.98 - 3.18 (12H, m), 3.37 - 3.45 (2H, m), 3.61 (1H, d), 3.74 - 3.88 (1H, m), 4.47 - 4.57 (OH, m), 4.67 - 4.72 (1H, m), 5.00 - 5.12 (1H, m), 6.83 - 6.91 (1H, m), 7.09 - 7.16 (1H, m), 7.31 - 7.36 (1H, m)

30

Examples 35 - 40 (see Table I below) were made using the method of Example 25.

EXAMPLE 41

This Example illustrates the preparation of 1-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-2,3-dihydro-1*H*-indene-1-carboxylic acid

4-[[4-(3,4-Dichlorophenoxy)-1-piperidinyl]methyl]-1,2-cyclopentanediol (0.20 g)
5 was dissolved in dichloromethane (10 mL) and sodium carbonate (0.206 g) was added. The suspension was cooled to 0°C. Lead tetraacetate (0.248 g) was added over 20 minutes. The mixture was stirred for 40 min at 0 C.

The suspension was filtered through a plug of cotton wool into a solution of 1-amino-2,3-dihydro-1*H*-indene-1-carboxylic acid (0.098 g), hydrochloric acid (0.1 mL),
10 triethylamine (0.1 mL) and methanol (10 mL). Sodium cyanoborohydride (0.052 g) was added and the reaction mixture was stirred for 16 h at room temperature. The solvents were evaporated and the residue was redissolved in acetonitrile/water and AcOH was added. This was purified by HPLC (5% MeCN/95%NH₄OAc aq (0.1%) gradient to 50% MeCN/50%NH₄OAc) to give title compound (93 mg).

15 MS [M+H]⁺ (ES+) 503/505.

¹H NMR δ (CD₃OD + NaOD) 1.17 - 1.27 (1H, m), 1.29 - 1.41 (2H, m), 1.46 - 1.54 (1H, m), 1.54 - 1.70 (3H, m), 1.83 - 1.93 (3H, m), 1.97 - 2.24 (6H, m), 2.42 - 2.52 (2H, m), 2.55 - 2.65 (2H, m), 2.71 - 2.80 (1H, m), 2.87 - 3.05 (2H, m), 4.22 - 4.31 (1H, m), 6.74 - 6.80 (1H, m), 6.97 - 7.03 (4H, m), 7.27 (1H, d), 7.44 (1H, d)

20

EXAMPLE 42

This Example illustrates the preparation of methyl 2-[(4-[[4-(3,4-dichlorophenoxy)piperidin-1-yl]methyl]piperidin-1-yl)methyl]benzoate

4-(3,4-Dichlorophenoxy)-1-(piperidin-4-ylmethyl)piperidine (0.5 g) was dissolved
25 in acetonitrile (2 mL) and to the solution was added methyl 2-(bromomethyl)benzoate (0.56 g) and DIPEA (0.25 mL). The reaction mixture was stirred at room temperature overnight then concentrated by evaporation under reduced pressure. The residue was partitioned between ethyl acetate and water, the organic phase was washed with brine, dried (MgSO₄), filtered and concentrated to give an oil. This was purified by
30 chromatography eluting with 5% methanol in dichloromethane then by HPLC (25% MeCN/75%NH₄OAc aq (0.1%) gradient to 95% MeCN/5%NH₄OAc) to give the title compound as an oil 0.4 g.

MS [M+H]⁺ (ES+) 491/493.

^1H NMR $\delta_{(\text{CDCl}_3)}$ 1.10 - 1.24 (2H, m), 1.46 (1H, qd), 1.63 - 2.05 (8H, m), 2.15 - 2.28 (4H, m), 2.62 - 2.71 (2H, m), 2.76 - 2.82 (2H, m), 3.74 (2H, s), 3.87 (3H, s), 4.23 (1H, quintet), 6.74 (1H, dd), 6.99 (1H, d), 7.25 - 7.32 (2H, m), 7.37 - 7.46 (2H, m), 7.68 (1H, d).

5 Example 43 (see Table I below) were made using the method of Example 42.

EXAMPLE 44

This Example illustrates the preparation of methyl 2-[[4-[[4-(2,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]methyl]-5-fluoro-benzoate

10 4-(2,4-Dichlorophenoxy)-1-(4-piperidinylmethyl)-piperidine dihydrochloride (0.26 g) was added to acetonitrile (3 mL) and treated with triethylamine (0.26 mL). After stirring for 5min, methyl 2-(bromomethyl)-5-fluoro benzoate (0.15 g) was added and the reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated *in vacuo* and crude product was purified by flash chromatography, eluting with 2%
15 methanol and 0.1% triethylamine in dichloromethane, giving the title compound contaminated with triethylamine hydrochloride.
MS $[\text{M}+\text{H}]^+$ (ES+) 509/511

Examples 45, 48-50 were prepared following the method of example 44.

20

EXAMPLE 46

This Example illustrates the preparation of 1-methylethyl- 3-[[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]methyl]-2-pyridinecarboxylate

 4-(3,4-Dichlorophenoxy)-1-(4-piperidinylmethyl)-piperidine (0.3 g) and 1-
25 methylethyl-3-formyl-2-pyridinecarboxylate (0.17 g) were added to a mixture of THF (3 mL) and acetic acid (0.5 mL). The mixture was stirred at room temperature for 5min then sodium triacetoxyborohydride (0.28 g) was added. The mixture was stirred overnight then poured into a saturated solution of sodium bicarbonate. The product was extracted with ethyl acetate, the organic phase was washed with brine, dried (MgSO_4), filtered and
30 concentrated *in vacuo*. The residue was purified by flash chromatography, eluting with 3% methanol and 0.1% triethylamine in dichloromethane, giving the title compound as a clear oil (0.24 g).

^1H NMR $\delta_{(\text{CD}_3\text{OD})}$ 1.13 - 1.28 (2H, m), 1.43 (6H, d), 1.50 - 1.65 (1H, m), 1.69 - 1.83

(4H, m), 1.96 - 2.11 (4H, m), 2.23 (2H, d), 2.27 - 2.37 (2H, m), 2.67 - 2.84 (4H, m), 3.72 (2H, s), 4.35 - 4.45 (1H, m), 5.26 (1H, t), 6.90 (1H, dd), 7.11 (1H, d), 7.39 (1H, d), 7.52 (1H, dd), 7.93 (1H, dd), 8.49 (1H, dd)

5 Examples 47, 60 - 66 (Table I below) were prepared following the method of Example 46.

EXAMPLES 51-59

10 Examples 51-59 (Table I below) were made from Examples 42-50 by the methods of Example 77 (LiOH, Examples 51, 53, 54, 57, 58, 59), Example 25 (HCl, Examples 55, 56) or Example 90 (KOTMS, Example 52).

EXAMPLE 67

15 This Example illustrates the preparation of methyl 4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidineacetate

 To a stirred solution of 4-(3,4-dichlorophenoxy)-1-(4-piperidinylmethyl)-piperidine (0.23 g) and DIPEA (0.164 mL) in DMF at RT was added methyl bromoacetate (0.076 mL). The reaction was heated at 60°C for 16 h. Saturated sodium bicarbonate solution (30 mL) was then added to the cooled solution and the product was extracted into ethyl acetate (3 x 20 mL). The combined organics were washed with brine (10 mL) and then dried, filtered and evaporated to leave a colourless oil (0.135 g).

MS [M+H]⁺ (ES+) 415/417

25 Examples 68-72 (see Table I) were prepared analogously to Example 67 from the appropriate amine.

EXAMPLE 73

 This Example illustrates the preparation of methyl (2R)-2-(4-[[4-(3,4-dichlorophenoxy)piperidin-1-yl]methyl]piperidin-1-yl)propanoate

30 Diethyl ether (10 mL) and dimethylformamide (2 mL) were added to 4-(3,4-dichlorophenoxy)-1-(piperidin-4-ylmethyl)piperidine (0.32 g) and the mixture was sonicated (cleaning bath) until it became clear. Methyl (2S)-2-bromopropanoate (0.16 g) and triethylamine (0.6 mL) were added and the mixture was stirred at room temperature

overnight. The reaction mixture was poured into water and was extracted with diethyl ether. The diethyl ether was washed with brine, dried (MgSO_4), filtered and concentrated under reduced pressure to give an oil. Crude product was purified by chromatography, eluting with 95 : 5 : 0.1 dichloromethane : methanol : aqueous ammonia to give the title compound as an oil (0.25 g).

MS $[\text{M}+\text{H}]^+$ (ES+) 429/431

Examples 74-76 (see Table I) were prepared analogously to Example 73.

10

EXAMPLE 77

This Example illustrates the preparation of 4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidineacetic acid.

Methyl 4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidineacetate (0.135 g) and lithium hydroxide (0.136 g) in 3 : 1 methanol/water (2 mL) was stirred at RT for 16 h. The reaction mixture was acidified to pH 4 with acetic acid and purified by HPLC (10% MeCN/90% NH_4OAc aq (0.1%) gradient to 70% MeCN/30% NH_4OAc) to provide the title compound as a white solid (0.030 g).

MS $[\text{M}+\text{H}]^+$ (ES+) 401/403.

^1H NMR $\delta_{(\text{CD}_3\text{OD})}$ 1.52 (2H, qd), 1.72 - 1.92 (3H, m), 1.98 - 2.09 (4H, m), 2.34 (2H, d), 2.38 - 2.45 (2H, m), 2.72 - 2.83 (2H, m), 3.01 (2H, td), 3.56 - 3.67 (4H, m), 4.35 - 4.49 (1H, m), 6.90 (1H, dd), 7.11 (1H, d), 7.39 (1H, d).

Examples 78-86 (see Table I) were prepared analogously to Example 77 from the appropriate ester.

25

EXAMPLE 87

This Example illustrates the preparation of methyl 4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]- α,α -dimethyl-1-piperidine propanoate

To a stirred solution of 4-[[4-(3,4-dichlorophenoxy)piperidin-1-yl]methyl]piperidine (0.175 g) and 2,2-dimethyl-3-oxopropanoic acid methyl ester (80 mg) in THF (0.5 mL) was added sodium triacetoxymethylborohydride (162 mg) and acetic acid (0.041 mL). The reaction mixture was stirred at room temperature overnight. Saturated sodium bicarbonate solution (30 mL) was added and the product was extracted into ethyl acetate (3

x 20 mL). The combined organics were washed with brine (10 mL) and dried (MgSO₄), filtered and evaporated to leave an oil (0.17 g). A portion (0.080 g) was purified by HPLC (5% MeCN/95%NH₄OAc aq (0.1%) gradient to 5% MeCN/95%NH₄OAc) to give the title compound as an oil (0.012 g).

5 MS [M+H]⁺ (ES+) 457/459.

¹H NMR δ_(CDCl₃) 1.15 (6H, s), 1.16 (1H, qd), 1.34 - 1.45 (1H, m), 1.58 - 1.62 (2H, m), 1.62 - 1.66 (2H, m), 1.71 - 1.82 (2H, m), 1.90 - 2.00 (2H, m), 2.07 - 2.16 (3H, m), 2.16 - 2.26 (2H, m), 2.45 (2H, s), 2.60 - 2.70 (2H, m), 2.70 - 2.77 (2H, m), 3.65 (3H, s), 4.18 - 4.27 (1H, m), 6.74 (1H, dd), 6.99 (1H, d), 7.30 (1H, d).

10

Examples 88 & 89 (see Table I) were prepared analogously to Example 87 from the appropriate amines.

EXAMPLE 90

15 This Example illustrates the preparation of 4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-α,α-dimethyl-1-piperidine propanoic acid.

To a stirred solution of methyl 4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-α,α-dimethyl-1-piperidine propanoate (0.080 g) in THF (1 mL) at RT was added potassium trimethylsilanolate (27 mg). After 16 h the reaction mixture was incomplete and
20 further potassium trimethylsilanolate (27 mg) was added. After a further 1 h the reaction solvent was evaporated and the residue was redissolved in acetonitrile and purified by HPLC (5% MeCN/95%NH₄OAc aq (0.1%) gradient to 60% MeCN/40%NH₄OAc) to give the title compound (0.036 g).

MS [M+H]⁺ (ES+) 443/445.

25 ¹H NMR δ_(CD₃OD) 1.22 (6H, s), 1.47 (2H, q), 1.68 - 1.81 (2H, m), 1.79 - 1.88 (1H, m), 1.93 - 2.05 (4H, m), 2.27 (2H, d), 2.33 (2H, t), 2.67 - 2.76 (2H, m), 2.95 - 3.02 (2H, m), 3.04 (2H, s), 3.45 - 3.52 (2H, m), 4.33 - 4.42 (1H, m), 6.87 (1H, dd), 7.08 (1H, d), 7.36 (1H, d).

30 Example 91 & 92 (Table I) were prepared analogously to Example 90 from the appropriate esters

EXAMPLE 93

This Example illustrates the preparation of 4-[[4-(3,4-Dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidine propanoic acid dihydrochloride

To a stirred solution of 4-[[4-(3,4-dichlorophenoxy)piperidin-1-yl]methyl]piperidine (0.175 g) in isopropanol (0.4 mL) at RT was added acrylic acid (0.038 mL). After 16 h the reaction mixture was purified by HPLC (5% MeCN/95%NH₄OAc aq (0.1%) gradient to 50% MeCN/50%NH₄OAc). Treatment of the product with 2 M HCl at 40 °C for 15 min followed by evaporation left a yellow solid. This was triturated with diethyl ether (3 mL) and the residual solid was partially dissolved in 4 : 1 dichloromethane/methanol. The supernatant was evaporated to provide the title compound as a solid (0.014 g).

MS [M+H]⁺ (ES+) 415/417.

¹H NMR $\delta_{(D_2O)}$ 1.63 (2H, qd), 1.91 - 2.05 (1H, m), 2.09 - 2.21 (2H, m), 2.26 (2H, d), 2.29 - 2.36 (1H, m), 2.40 (1H, d), 2.87 (2H, t), 3.08 (2H, t), 3.14 - 3.22 (2H, m), 3.29 - 3.40 (2H, m), 3.44 (2H, t), 3.52 (1H, d), 3.64 - 3.79 (3H, m), 4.61 - 4.70 (1H, m), 6.96 - 7.03 (1H, m), 7.24 - 7.29 (1H, m), 7.50 (1H, d).

EXAMPLE 94

This Example illustrates the preparation of 4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinebutanoic acid.

4-(3,4-Dichlorophenoxy)-1-(4-piperidinylmethyl)-piperidine (0.20 g) and methyl 4-bromo-butanoate (0.10 g) were dissolved in acetone (20 mL) and potassium carbonate (0.08 g) was added. The reaction mixture was stirred for 16 h at room temperature. The reaction mixture was filtered and the solvents were evaporated to give the title compound (18 mg).

MS [M+H]⁺ (ES+) 443/445

Example 95 & 96 (Table I) were prepared analogously to Example 94 from the appropriate halo esters.

Examples 97-99 (Table I) were prepared from the appropriate esters by the method of Example 25.

EXAMPLE 100

This Example illustrates the preparation of 4-(3,4-dichlorophenoxy)-1-[[1-(2H-tetrazol-5-yl)methyl]-4-piperidinyl]methyl]-piperidine

4-[[4-(3,4-Dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidineacetonitrile (0.26 g), azidotrimethylsilane (0.5 mL), dibutyltin oxide (0.17 g) and toluene (10 mL) were heated together at 110 °C, in a sealed tube, for 20 hours, cooled and evaporated. The residue was dissolved in methanol, and filtered through reverse-phase silica to remove the tin by-products. The product was further purified by reverse-phase HPLC (25% MeCN/75%NH₄OAc aq (0.1%) gradient to 95% MeCN/5%NH₄OAc). This gave the title compound as a solid (0.24 g).

MS [M+H]⁺ (APCI+) 425/427.

¹H NMR δ_(CD₃OD) 1.16 - 1.38 (2H, m), 1.71 - 1.84 (5H, m), 1.91 - 2.05 (2H, m), 2.37 - 2.49 (2H, m), 2.50 - 2.69 (4H, m), 2.79 - 2.98 (2H, m), 3.20 - 3.25 (2H, m), 4.12 (2H, s), 4.33 - 4.46 (1H, m), 6.81 (1H, dd), 7.04 (1H, d), 7.29 (1H, d)

Example 101 (Table I) was prepared analogously to Example 100 from the appropriate nitrile.

EXAMPLE 102

This Example illustrates the preparation of *N*-[2-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]ethyl]-1,1,1-trifluoro-methanesulfonamide

4-[[4-(3,4-Dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidineethanamine (0.28 g) in dichloromethane (25 mL) was cooled to -78 °C under nitrogen, and triflic anhydride (0.35 mL) was added dropwise. After 5 minutes the reaction was quenched with excess aqueous ammonia solution, warmed to room temperature, and evaporated. The product was purified by reverse-phase HPLC (25% MeCN/75%NH₄OAc aq (0.1%) gradient to 95% MeCN/5%NH₄OAc). This gave the title compound as a solid (0.08 g).

MS [M+H]⁺ (APCI+) 518/520.

¹H NMR δ_(CD₃OD) 1.25 (2H, dd), 1.54 - 1.72 (3H, m), 1.79 (2H, d), 1.85 - 1.95 (2H, m), 2.18 (2H, d), 2.25 (2H, t), 2.35 (2H, td), 2.57 - 2.74 (4H, m), 3.11 (2H, d), 3.25 (2H, t), 4.19 - 4.43 (1H, m), 6.79 (1H, dd), 7.00 (1H, d), 7.28 (1H, d)

Examples 103 and 104 (Table I) were prepared analogously to Example 102 from the appropriate amines.

TABLE I

Example	Name	M+H	¹ H NMR
2	4-[[4-(2,4-Dichloro-3-methylphenoxy)-1-piperidiny]methyl]- α -phenyl-1-piperidineacetic acid	491/493	$\delta_{(\text{CDCl}_3)}$ 1.56 - 1.72 (3H, m), 1.83 - 1.97 (6H, m), 2.23 (2H, d), 2.30 - 2.39 (2H, m), 2.45 (3H, s), 2.50 - 2.52 (1H, m), 2.62 - 2.68 (2H, m), 2.76 - 2.84 (1H, m), 3.39 (1H, d), 3.71 (2H, d), 4.32 (1H, s), 4.57 (1H, s), 6.71 (1H, d), 7.17 (1H, d), 7.36 - 7.38 (3H, m), 7.53 - 7.56 (2H, m)
3	4-[[4-(3,4-Dichlorophenoxy)-1-piperidiny]methyl]- α -(4-fluorophenyl)-1-piperidineacetic acid	495/497	$\delta_{(\text{CDCl}_3)}$ 1.56 - 1.78 (5H, m), 1.84 - 1.98 (4H, m), 2.18 - 2.32 (4H, m), 2.37 - 2.53 (1H, m), 2.57 - 2.67 (2H, m), 2.72 - 2.84 (1H, m), 3.36 - 3.43 (1H, m), 3.64 - 3.72 (1H, m), 4.19 - 4.26 (1H, m), 4.54 (1H, s), 6.72 (1H, dd), 6.96 (1H, d), 7.07 (2H, t), 7.24 - 7.32 (1H, m), 7.55 (2H, dd)
4	4-[[4-(3,4-Dichlorophenoxy)-1-piperidiny]methyl]- α -(2-methoxyphenyl)-1-piperidineacetic acid	507/509	$\delta_{(\text{CDCl}_3)}$ 1.55 - 1.79 (5H, m), 1.86 - 2.00 (4H, m), 2.16 - 2.27 (4H, m), 2.39 - 2.74 (4H, m), 2.87 (1H, t), 3.37 (1H, d), 3.69 - 3.78 (1H, m), 3.87 (3H, s), 4.18 - 4.26 (1H, m), 5.03 (1H, s), 6.72 (1H, dd), 6.91 - 7.03 (3H, m), 7.25 - 7.31 (1H, m), 7.37 (1H, t), 7.51 (1H, d)
5	4-[[4-(3,4-Dichlorophenoxy)-1-piperidiny]methyl]- α -(2-methylphenyl)-1-piperidineacetic acid	491/493	$\delta_{(\text{CDCl}_3)}$ 1.47 - 1.75 (4H, m), 1.80 - 1.95 (5H, m), 2.12 - 2.23 (4H, m), 2.43 - 2.66 (6H, m), 2.76 - 2.90 (1H, m), 3.39 (1H, d), 3.49 (1H, s), 3.84 - 3.96 (1H, m), 4.14 - 4.25 (1H, m), 4.76 (1H, s), 6.72 (1H, dd), 6.96 (1H, d), 7.16 - 7.32 (4H, m), 7.78 (1H, d)

6	4-[[4-(3,4-Dichlorophenoxy)-1-piperidinyl]methyl]- α -(4-methylphenyl)-1-piperidineacetic acid	491/493	δ_{CDCl_3} 1.55 - 1.79 (5H, m), 1.81 - 1.96 (4H, m), 2.14 - 2.25 (4H, m), 2.35 (3H, s), 2.43 - 2.73 (4H, m), 2.76 - 2.87 (1H, m), 3.47 (1H, d), 3.68 - 3.77 (1H, m), 4.15 - 4.25 (1H, m), 4.54 (1H, s), 6.72 (1H, dd), 6.96 (1H, d), 7.18 (2H, d), 7.26 - 7.31 (1H, m), 7.42 (2H, d)
7	4-[[4-(2,4-Dichloro-3-methylphenoxy)-1-piperidinyl]methyl]- α -(2-methoxyphenyl)-1-piperidineacetic acid	521/523	δ_{CDCl_3} 1.55 - 1.68 (2H, m), 1.74 - 2.00 (5H, m), 2.16 - 2.28 (4H, m), 2.45 (3H, s), 2.57 - 2.90 (6H, m), 3.41 (1H, d), 3.66 - 3.77 (1H, m), 3.87 (3H, s), 4.24 - 4.35 (1H, m), 5.09 (1H, s), 6.72 (1H, d), 6.92 - 7.02 (2H, m), 7.17 (1H, d), 7.36 (1H, dd), 7.53 (1H, d)
8	4-[[4-(2,4-Dichloro-3-methylphenoxy)-1-piperidinyl]methyl]- α -(2-methylphenyl)-1-piperidineacetic acid	505/507	δ_{CDCl_3} 1.73 - 1.96 (8H, m), 2.14 - 2.28 (5H, m), 2.45 (3H, s), 2.53 (3H, s), 2.57 - 2.66 (4H, m), 2.75 - 2.86 (1H, m), 3.36 (1H, d), 3.80 - 3.91 (1H, m), 4.24 - 4.32 (1H, m), 4.73 (1H, s), 6.71 (1H, d), 7.14 - 7.24 (4H, m), 7.77 (1H, d)
9	4-[[4-(2,4-Dichloro-3-methylphenoxy)-1-piperidinyl]methyl]- α -(4-methylphenyl)-1-piperidineacetic acid	505/507	δ_{CDCl_3} 1.55 - 1.94 (9H, m), 2.14 - 2.27 (4H, m), 2.35 (3H, s), 2.45 (3H, s), 2.52 - 2.82 (5H, m), 3.46 (1H, d), 3.64 - 3.73 (1H, m), 4.24 - 4.32 (1H, m), 4.47 (1H, s), 6.71 (1H, d), 7.17 (3H, d), 7.43 (2H, d)

10	4-[[4-(4-Chloro-2-methylphenoxy)-1-piperidinyl]methyl]- α -(2-methoxyphenyl)-1-piperidineacetic acid	487/489	$\delta_{(\text{CDCl}_3)}$ 1.58 - 1.65 (2H, m), 1.70 - 1.80 (4H, m), 1.85 - 1.95 (4H, m), 2.15 - 2.26 (7H, m), 2.46 - 2.74 (3H, m), 2.80 - 2.91 (1H, m), 3.42 (1H, d), 3.68 - 3.77 (1H, m), 3.87 (3H, s), 4.19 - 4.28 (1H, m), 5.09 (1H, s), 6.70 (1H, d), 6.91 - 7.11 (4H, m), 7.36 (1H, dd), 7.53 (1H, d)
11	4-[[4-(4-Chloro-2-methylphenoxy)-1-piperidinyl]methyl]- α -(2-methylphenyl)-1-piperidineacetic acid	471/473	$\delta_{(\text{CDCl}_3)}$ 1.48 - 1.95 (11H, m), 2.13 (3H, s), 2.25 (2H, t), 2.46 - 2.90 (8H, m), 3.36 (1H, d), 3.83 - 3.93 (1H, m), 4.19 - 4.28 (1H, m), 4.78 (1H, s), 6.70 (1H, d), 7.02 - 7.11 (2H, m), 7.15 - 7.25 (3H, m), 7.74 (1H, d)
12	α -{4-[[4-(3,4-Dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-2,4-dimethoxy-5-pyrimidineacetic acid	539/541	$\delta_{(\text{CDCl}_3)}$ 1.48 - 2.80 (19H, m), 3.27 - 3.35 (1H, m), 3.51 (3H, s), 3.99 (3H, s), 4.29 - 4.37 (1H, m), 4.55 (1H, s), 6.73 (1H, dd), 6.98 (1H, d), 7.31 (1H, d), 8.06 (1H, s)
13	4-[[4-(4-Chloro-2-methylphenoxy)-1-piperidinyl]methyl]- α -(4-methylphenyl)-1-piperidineacetic acid	471/473	$\delta_{(\text{CDCl}_3)}$ 1.56 - 1.79 (5H, m), 1.83 - 1.94 (4H, m), 2.13 - 2.27 (7H, m), 2.35 (3H, s), 2.44 - 2.95 (5H, m), 3.48 (1H, d), 3.71 (1H, d), 4.19 - 4.28 (1H, m), 4.50 (1H, s), 6.70 (1H, d), 7.03 - 7.11 (2H, m), 7.18 (2H, d), 7.43 (2H, d)

14	α -[3-(Acetylamino)phenyl]-4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidineacetic acid	534/536	δ_{CDCl_3} 1.46 - 1.64 (2H, m), 1.68 - 1.83 (3H, m), 1.87 - 1.97 (2H, m), 2.05 - 2.25 (7H, m), 2.36 - 2.77 (8H, m), 3.33 - 3.68 (2H, m), 4.22 (1H, s), 4.41 (1H, s), 6.73 (1H, dd), 6.96 - 7.02 (2H, m), 7.22 - 7.33 (2H, m), 7.49 (1H, s), 8.09 (1H, d)
15	4-[[4-(2,4-Dichloro-3-methylphenoxy)-1-piperidinyl]methyl]- α -(4-fluorophenyl)-1-piperidineacetic acid	509/511	δ_{CDCl_3} 1.54 - 2.47 (18H, m), 2.61 - 2.72 (2H, m), 3.28 - 3.35 (1H, m), 3.54 - 3.61 (1H, m), 4.29 - 4.42 (2H, m), 6.71 (1H, d), 7.05 (2H, t), 7.17 (1H, d), 7.54 (2H, dd)
16	4-[[4-(2,4-Dichlorophenoxy)-1-piperidinyl]methyl]- α -phenyl-1-piperidineacetic acid	477/479	$\delta_{\text{CD}_3\text{OD}}$ 1.48 - 1.61 (2H, m), 1.75 - 1.89 (4H, m), 1.90 - 2.04 (4H, m), 2.28 (2H, d), 2.33 - 2.41 (2H, m), 2.67 - 2.77 (3H, m), 2.96 (2H, t), 4.37 - 4.50 (2H, m), 7.07 (1H, d), 7.22 (1H, dd), 7.39 (1H, d), 7.42 - 7.46 (3H, m), 7.54 - 7.58 (2H, m)
17	4-[[4-(3,4-Dichlorophenoxy)-1-piperidinyl]methyl]-4-hydroxy- α -phenyl-1-piperidineacetic acid	493/495	$\delta_{\text{CD}_3\text{OD}}$ 1.64 - 1.82 (4H, m), 1.85 - 2.03 (3H, m), 2.40 (2H, s), 2.49 - 2.57 (2H, m), 2.81 - 2.90 (3H, m), 2.98 - 3.16 (2H, m), 3.51 - 3.72 (2H, m), 4.32 - 4.39 (1H, m), 4.52 (1H, s), 6.87 (1H, dd), 7.08 (1H, d), 7.37 (1H, d), 7.42 - 7.47 (3H, m), 7.55 - 7.60 (2H, m)

18	4-[[4-(3,4-Dichlorophenoxy)-1-piperidinyl]methyl]-4-hydroxy- α -(4-methylphenyl)-1-piperidineacetic acid	507/509	δ_{CD3OD} 1.64 - 1.81 (4H, m), 1.82 - 2.02 (4H, m), 2.36 (3H, s), 2.40 (2H, s), 2.49 - 2.57 (2H, m), 2.81 - 2.89 (2H, m), 2.92 - 3.06 (2H, m), 3.62 - 3.75 (2H, m), 4.32 - 4.39 (1H, m), 4.47 (1H, s), 6.87 (1H, dd), 7.08 (1H, d), 7.26 (2H, d), 7.36 (1H, d), 7.44 (2H, d)
19	4-[[4-(3,4-Dichlorophenoxy)-1-piperidinyl]methyl]-4-hydroxy- α -(2-methoxyphenyl)-1-piperidineacetic acid	523/525	δ_{CD3OD} 1.65 - 1.80 (4H, m), 1.93 - 2.04 (4H, m), 2.40 (2H, s), 2.48 - 2.57 (2H, m), 2.81 - 2.89 (2H, m), 2.94 - 3.06 (2H, m), 3.67 - 3.77 (2H, m), 3.91 (3H, s), 4.32 - 4.39 (1H, m), 4.98 (1H, s), 6.87 (1H, dd), 7.03 (1H, td), 7.08 (1H, d), 7.09 - 7.12 (1H, m), 7.36 (1H, d), 7.41 - 7.46 (1H, m), 7.53 (1H, dd)
21	4-[[4-(2,6-Dichlorophenoxy)-1-piperidinyl]methyl]- α -phenyl-1-piperidineacetic acid	477/479	δ_{CD3OD} 1.37 - 1.53 (2H, m), 1.67 - 1.80 (4H, m), 1.81 - 1.96 (3H, m), 2.19 (2H, d), 2.24 - 2.35 (2H, m), 2.56 - 2.74 (3H, m), 2.80 - 2.92 (2H, m), 3.61 - 3.80 (1H, m), 4.28 - 4.35 (1H, m), 4.38 - 4.46 (1H, m), 6.94 (1H, dd), 6.99 (1H, dd), 7.10 (1H, t), 7.31 - 7.37 (3H, m), 7.43 - 7.50 (2H, m)
26	(S)-4-[[4-(3,4-Dichlorophenoxy)-1-piperidinyl]methyl]- α -phenyl-1-piperidineacetic acid	477/479	$\delta_{\text{CD3OD} + \text{NaOD}}$ 1.25 - 1.38 (2H, m), 1.44 - 1.62 (2H, m), 1.68 - 2.06 (8H, m), 2.27 - 2.41 (4H, m), 2.69 - 2.78 (2H, m), 2.97 (1H, t), 4.35 - 4.47 (2H, m), 6.87 (1H, dd), 7.09 (1H, d), 7.37 (1H, d), 7.44 (3H, t), 7.54 - 7.59 (2H, m)
28	Methyl 4-[[4-(2,4-dichloro-3-methylphenoxy)-1-piperidinyl]methyl]- α -phenyl-1-piperidineacetate (α^1R)-	505/507	

29	(α^1S)-1,1-Dimethylethyl 4-[[4-(2,4-dichloro-3-methylphenoxy)-1-piperidinyl]methyl]- α -phenyl-1-piperidineacetate	547/549	
30	(α^1R)- Methyl 4-[[4-(3,4-dichloro-2-methylphenoxy)-1-piperidinyl]methyl]- α -phenyl-1-piperidineacetate	505/507	
31	(α^1R)- Methyl 4-[[4-(3,4-dichloro-2-methylphenoxy)-1-piperidinyl]methyl]- α -phenyl-1-piperidineacetate	505/507	
32	Methyl (S)- 4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]- α -(1-methylethyl)-1-piperidineacetate	457/459	
33	1,1-Dimethylethyl 4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]- α , α -dimethyl-1-piperidineacetate	485/487	

35	(α^1R)-4-[[4-(2,4-Dichloro-3-methylphenoxy)-1-piperidiny]methyl]- α -phenyl-1-piperidineacetic acid	491/493	$\delta_{(CD_3OD)}$ 1.43 - 1.63 (2H, m), 1.78 - 1.89 (4H, m), 1.91 - 2.05 (3H, m), 2.15 (1H, s), 2.32 (2H, d), 2.38 - 2.48 (5H, m), 2.69 - 2.80 (3H, m), 2.91 - 3.05 (2H, m), 4.40 - 4.52 (2H, m), 6.94 (1H, d), 7.25 (1H, d), 7.43 - 7.45 (3H, m), 7.55 - 7.58 (2H, m)
36	(α^1S)-4-[[4-(2,4-Dichloro-3-methylphenoxy)-1-piperidiny]methyl]- α -phenyl-1-piperidineacetic acid	491/493	$\delta_{(CD_3OD)}$ 1.42 - 1.62 (2H, m), 1.77 - 1.90 (4H, m), 1.90 - 2.05 (4H, m), 2.30 (2H, d), 2.35 - 2.45 (5H, m), 2.72 (3H, t), 2.97 (2H, t), 4.40 - 4.49 (2H, m), 6.93 (1H, d), 7.25 (1H, d), 7.42 - 7.46 (3H, m), 7.53 - 7.59 (2H, m)
37	(α^1R)-4-[[4-(3,4-Dichloro-2-methylphenoxy)-1-piperidiny]methyl]- α -phenyl-1-piperidineacetic acid	491/493	$\delta_{(CD_3OD)}$ 1.43 - 1.67 (2H, m), 1.76 - 1.94 (4H, m), 1.95 - 2.10 (4H, m), 2.30 - 2.37 (5H, m), 2.45 (2H, t), 2.75 (3H, t), 3.01 (2H, t), 4.41 - 4.52 (2H, m), 6.93 (1H, d), 7.30 (1H, d), 7.47 (3H, dd), 7.59 (2H, q)
38	(α^1S)-4-[[4-(3,4-Dichloro-2-methylphenoxy)-1-piperidiny]methyl]- α -phenyl-1-piperidineacetic acid	491/493	$\delta_{(CD_3OD)}$ 1.30 - 1.54 (2H, m), 1.65 - 1.81 (4H, m), 1.81 - 1.98 (4H, m), 2.19 - 2.25 (5H, m), 2.28 - 2.39 (2H, m), 2.57 - 2.70 (3H, m), 2.82 - 2.98 (2H, m), 4.29 - 4.40 (2H, m), 6.81 (1H, d), 7.18 (1H, d), 7.32 - 7.39 (3H, m), 7.43 - 7.51 (2H, m)
39	(S)-4-[[4-(3,4-Dichlorophenoxy)-1-piperidiny]methyl]- α -(1-methylethyl)-1-piperidineacetic acid	443/445	$\delta_{(CD_3OD + NaOD)}$ 1.02 (3H, d), 1.14 (3H, d), 1.26 - 1.38 (3H, m), 1.42 - 1.64 (2H, m), 1.73 - 1.85 (2H, m), 1.98 - 2.07 (4H, m), 2.28 - 2.39 (2H, m), 2.40 - 2.49 (2H, m), 2.75 - 2.84 (2H, m), 2.97 - 3.04 (2H, m), 3.46 - 3.58 (2H, m), 4.39 - 4.46 (1H, m), 6.89 (1H, dd), 7.10 (1H, d), 7.38 (1H, d)

40	4-[[4-(3,4-Dichlorophenoxy)-1-piperidinyl]methyl]- α , α -dimethyl-1-piperidineacetic acid	429/431	$\delta_{(\text{CD}_3\text{OD} + \text{NaOD})}$ 1.17 - 1.55 (8H, m), 1.61 - 1.77 (2H, m), 1.77 - 2.01 (7H, m), 2.23 - 2.40 (3H, m), 2.63 - 2.75 (2H, m), 2.88 (2H, t), 3.31 - 3.42 (1H, m), 4.28 - 4.39 (1H, m), 6.79 (1H, dd), 7.01 (1H, d), 7.28 (1H, d)
43	methyl 2-[(4-{[4-(2,4-Dichlorophenoxy)piperidin-1-yl]methyl}piperidin-1-yl)methyl]benzoate	491/493	
51	2-[(4-{[4-(3,4-dichlorophenoxy)piperidin-1-yl]methyl}piperidin-1-yl)methyl]benzoic acid	477/479	$\delta_{(\text{CD}_3\text{OD})}$ 1.30 - 1.46 (2H, m), 1.70 - 1.83 (3H, m), 1.95 - 2.11 (4H, m), 2.25 - 2.41 (4H, m), 2.69 - 2.79 (2H, m), 2.94 (2H, t), 3.31 - 3.41 (2H, m), 4.26 (2H, s), 4.41 (1H, dt), 6.90 (1H, dd), 7.11 (1H, d), 7.39 (2H, d), 7.51 (2H, dtd), 7.97 (1H, dd)
52	2-[[4-[[4-(2,4-Dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]methyl]-benzoic acid	477/479	$\delta_{(\text{CD}_3\text{OD} + \text{NaOD})}$ 1.19 - 1.34 (2H, m), 1.47 - 1.61 (1H, m), 1.69 - 1.76 (2H, m), 1.76 - 1.86 (2H, m), 1.93 - 2.08 (4H, m), 2.22 (2H, d), 2.29 - 2.37 (2H, m), 2.64 - 2.72 (2H, m), 2.89 - 2.95 (2H, m), 3.83 (2H, s), 4.41 - 4.48 (1H, m), 7.07 (1H, d), 7.16 - 7.28 (3H, m), 7.38 (1H, d), 7.41 - 7.45 (2H, m)
57	2-[[4-[[4-(3,4-Dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]methyl]-5-fluorobenzoic acid	495/497	$\delta_{(\text{CD}_3\text{OD})}$ 1.24 - 1.40 (2H, m), 1.66 - 1.77 (2H, m), 1.81 - 1.99 (5H, m), 2.34 (2H, d), 2.43 (2H, t), 2.71 - 2.79 (2H, m), 2.86 (2H, t), 3.22 - 3.29 (2H, m), 4.15 (2H, s), 4.31 - 4.39 (1H, m), 6.80 (1H, dd), 7.01 (1H, d), 7.11 (1H, td), 7.29 (1H, d), 7.31 (1H, dd), 7.56 (1H, dd)

58	4-[[4-[[4-(2,4-Dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]methyl]-3-fluorobenzoic acid	495/497	$\delta_{\text{(CD}_3\text{OD)}}$ 1.30 - 1.49 (2H, m), 1.82 - 1.96 (3H, m), 2.00 - 2.07 (2H, m), 2.11 - 2.22 (2H, m), 2.47 - 2.58 (2H, m), 2.69 (2H, d), 2.86 - 2.97 (2H, m), 3.03 - 3.22 (4H, m), 3.95 (2H, s), 4.60 - 4.69 (1H, m), 7.14 (1H, d), 7.28 (1H, dd), 7.44 - 7.51 (2H, m), 7.68 (1H, dd), 7.78 (1H, dd)
59	2-[[4-[[4-(3,4-Dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]methyl]-4-oxazolecarboxylic acid,	468/470	$\delta_{\text{(CD}_3\text{OD)}}$ 1.20 - 1.32 (2H, m), 1.77 (3H, d), 1.92 - 2.00 (2H, m), 2.08 - 2.15 (4H, m), 2.81 (2H, d), 2.90 (2H, d), 3.11 - 3.22 (4H, m), 3.64 (2H, s), 4.55 (1H, s), 6.85 (1H, dd), 7.10 (1H, d), 7.31 (1H, d), 8.06 (1H, s)
60	4-[[4-[[4-(3,4-Dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]methyl]-benzoic acid	477/479	$\delta_{\text{(CD}_3\text{OD)}}$ 1.29 (2H, q), 1.70 - 1.83 (5H, m), 1.93 - 2.01 (2H, m), 2.40 (2H, d), 2.44 - 2.58 (4H, m), 2.82 (2H, tt), 3.12 (2H, d), 3.88 (2H, s), 4.34 - 4.43 (1H, m), 6.81 (1H, dd), 7.03 (1H, d), 7.29 (1H, d), 7.33 (2H, d), 7.87 (2H, d)
61	3-[[4-[[4-(3,4-Dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]methyl]-benzoic acid	477/479	$\delta_{\text{(CD}_3\text{OD)}}$ 1.25 - 1.41 (2H, m), 1.66 - 1.78 (3H, m), 1.82 - 1.99 (4H, m), 2.32 (2H, d), 2.37 - 2.47 (2H, m), 2.59 - 2.79 (4H, m), 3.25 (2H, s), 4.00 (2H, s), 4.30 - 4.39 (1H, m), 6.79 (1H, dd), 7.01 (1H, d), 7.28 (1H, d), 7.31 - 7.42 (2H, m), 7.87 - 7.92 (2H, m)
62	2-[[4-[[4-(2,4-Dichloro-3-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]methyl]-benzoic acid	491/493	$\delta_{\text{(CD}_3\text{OD)}}$ 1.31 - 1.50 (2H, m), 1.81 - 1.93 (3H, m), 1.96 - 2.11 (4H, m), 2.39 (2H, d), 2.45 - 2.55 (5H, m), 2.77 - 2.85 (2H, m), 2.90 - 3.03 (2H, m), 3.34 - 3.40 (2H, m), 4.27 (2H, s), 4.46 - 4.54 (1H, m), 6.97 (1H, d), 7.28 (1H, d), 7.38 - 7.41 (1H, m), 7.51 (2H, dtd), 7.98 (1H, dd)

63	2-[[4-[[4-(3,4-Dichloro-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]methyl]-benzoic acid	491/493	$\delta_{\text{(CD}_3\text{OD)}}$ 1.26 - 1.42 (2H, m), 1.74 - 1.85 (3H, m), 1.92 - 2.09 (4H, m), 2.24 - 2.32 (2H, m), 2.30 (3H, s), 2.38 (2H, t), 2.69 (2H, t), 2.91 (2H, t), 3.30 - 3.39 (2H, m), 4.19 - 4.26 (2H, m), 4.37 - 4.47 (1H, m), 6.90 (1H, d), 7.26 (1H, d), 7.36 (1H, d), 7.48 (2H, quintet), 7.95 (1H, d)
64	[2-[[4-[[4-(2,4-Dichloro-3-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]methyl]phenoxy]-acetic acid	521/523	$\delta_{\text{(CD}_3\text{OD)}}$ 1.46 - 1.63 (2H, m), 1.69 - 1.95 (7H, m), 2.23 - 2.29 (2H, m), 2.31 - 2.40 (5H, m), 2.63 - 2.73 (2H, m), 2.79 - 2.91 (2H, m), 3.35 (2H, d), 4.11 (2H, s), 4.34 - 4.42 (1H, m), 4.57 (2H, s), 6.85 (1H, d), 6.94 (1H, t), 7.07 (1H, d), 7.16 (1H, d), 7.24 (1H, d), 7.35 (1H, t)
65	2-[[4-[[4-(2,4-Dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]methyl]-benzenesulfonic acid	(ES -ve) 511/513	$\delta_{\text{(CD}_3\text{OD)}}$ 1.18 - 1.40 (2H, m), 1.69 - 1.82 (3H, m), 1.89 - 2.02 (4H, m), 2.25 (2H, d), 2.31 - 2.41 (2H, m), 2.63 - 2.73 (2H, m), 2.98 (2H, t), 3.34 (2H, d), 4.34 - 4.44 (1H, m), 4.52 (2H, s), 6.98 (1H, d), 7.14 (1H, dd), 7.30 (1H, d), 7.39 - 7.51 (3H, m), 7.91 - 7.96 (1H, m)
66	2-[[4-[[4-(2,4-Dichloro-3-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]methyl]-benzenesulfonic acid	527/529	$\delta_{\text{(CD}_3\text{OD)}}$ 1.15 - 1.33 (2H, m), 1.66 - 2.02 (7H, m), 2.12 - 2.37 (7H, m), 2.57 - 2.68 (2H, m), 2.88 - 3.02 (2H, m), 3.28 - 3.40 (2H, m), 4.31 - 4.40 (1H, m), 4.51 (2H, s), 6.84 (1H, d), 7.15 (1H, d), 7.39 - 7.50 (3H, m), 7.90 - 7.96 (1H, m)

68	Methyl 4-[[4-(2,4-dichloro-3-methylphenoxy)-1-piperidinyl]methyl]-1-piperidineacetate	429/431	
69	Methyl 4-[[4-(4-chloro-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidineacetate	(ES-ve) 393/395	
70	Methyl 4-[[4-(2,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidineacetate	415/417	
71	Methyl 4-[[4-(3,4-dichloro-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidineacetate	429/433	
72	Methyl 4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-4-hydroxy-1-piperidineacetate	431/433	

74	Methyl (2 <i>S</i>)-2-(4-{[4-(3,4-dichlorophenoxy)piperidin-1-yl]methyl}piperidin-1-yl)propanoate	429/431	
75	(α <i>R</i>)-Methyl-4-[[4-(4-chloro-2-methylphenoxy)-1-piperidinyl]methyl]- α -methyl-1-piperidineacetate	(ES-ve) 407/409	
76	(α <i>S</i>)-Methyl-4-[[4-(4-chloro-2-methylphenoxy)-1-piperidinyl]methyl]- α -methyl-1-piperidineacetate	(ES-ve) 407/409	
78	4-[[4-(2,4-Dichloro-3-methylphenoxy)-1-piperidinyl]methyl]-1-piperidineacetic acid	415/417	$\delta_{\text{(CDCl}_3\text{)}}$ 1.45 - 1.61 (2H, m), 1.80 - 1.93 (3H, m), 1.96 - 2.10 (4H, m), 2.33 (2H, d), 2.38 - 2.48 (2H, m), 2.47 (3H, s), 2.71 - 2.82 (2H, m), 3.01 (2H, t), 3.55 - 3.68 (2H, m), 3.59 (2H, s), 4.44 - 4.54 (1H, m), 6.96 (1H, d), 7.27 (1H, d)
79	4-[[4-(4-Chloro-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidineacetic acid		$\delta_{\text{(CD}_3\text{OD)}}$ 1.45 - 1.61 (2H, m), 1.76 - 1.94 (3H, m), 1.97 - 2.09 (4H, m), 2.20 (3H, s), 2.32 (2H, d), 2.40 (2H, t), 2.69 - 2.78 (2H, m), 3.01 (2H, t), 3.57 - 3.66 (4H, m), 4.37 - 4.46 (1H, m), 6.89 (1H, d), 7.08 - 7.14 (2H, m)

80	[[4-(2,4-Dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidineacetic acid		$\delta_{\text{(CD}_3\text{OD)}}$ 1.32 - 1.48 (2H, m), 1.67 - 1.80 (3H, m), 1.84 - 1.96 (4H, m), 2.20 (2H, d), 2.25 - 2.34 (2H, m), 2.59 - 2.68 (2H, m), 2.83 - 2.95 (2H, m), 3.45 - 3.55 (4H, m), 4.34 - 4.42 (1H, m), 6.98 (1H, d), 7.14 (1H, dd), 7.30 (1H, d)
81	4-[[4-(3,4-Dichloro-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidineacetic acid	415/417	$\delta_{\text{(CD}_3\text{OD)}}$ 1.52 (2H, dd), 1.79 - 1.94 (3H, m), 1.99 - 2.08 (4H, m), 2.32 (3H, s), 2.38 (2H, d), 2.48 (2H, t), 2.77 (2H, t), 3.01 (2H, t), 3.55 - 3.64 (4H, m), 4.41 - 4.50 (1H, m), 6.93 (1H, d), 7.28 (1H, d)
82	4-[[4-(3,4-Dichlorophenoxy)-1-piperidinyl]methyl]-4-hydroxy-1-piperidineacetic acid	417/419	
83	(2R)-2-(4-{[4-(3,4-Dichlorophenoxy)piperidin-1-yl]methyl}piperidin-1-yl)propanoic acid	415/417	$\delta_{\text{(CD}_3\text{OD)}}$ 1.42 - 1.59 (5H, m), 1.71 - 2.12 (7H, m), 2.28 - 2.41 (4H, m), 2.70 - 2.80 (2H, m), 2.93 - 3.14 (2H, m), 3.49 - 3.62 (3H, m), 4.37 - 4.46 (1H, m), 6.91 (1H, dd), 7.12 (1H, d), 7.40 (1H, t)
84	(2S)-2-(4-{[4-(3,4-Dichlorophenoxy)piperidin-1-yl]methyl}piperidin-1-yl)propanoic acid	415/417	$\delta_{\text{(CD}_3\text{OD)}}$ 1.44 - 1.60 (5H, m), 1.73 - 2.12 (7H, m), 2.30 - 2.43 (4H, m), 2.71 - 2.81 (2H, m), 2.93 - 3.14 (2H, m), 3.50 - 3.62 (3H, m), 4.38 - 4.48 (1H, m), 6.91 (1H, dd), 7.12 (1H, d), 7.40 (1H, d)

85	(αR)-4-[[4-(4-Chloro-2-methylphenoxy)-1-piperidinyl]methyl]- α -methyl-1-piperidineacetic acid		$\delta_{(CD_3OD)}$ 1.45 - 1.61 (5H, m), 1.76 - 2.13 (7H, m), 2.20 (3H, s), 2.32 (2H, d), 2.41 (2H, t), 2.69 - 2.79 (2H, m), 2.94 - 3.14 (2H, m), 3.50 - 3.62 (3H, m), 4.37 - 4.46 (1H, m), 6.90 (1H, d), 7.08 - 7.14 (2H, m)
86	(αS)-4-[[4-(4-Chloro-2-methylphenoxy)-1-piperidinyl]methyl]- α -methyl-1-piperidineacetic acid		$\delta_{(CD_3OD)}$ 1.45 - 1.55 (5H, m), 1.75 - 1.91 (3H, m), 1.95 - 2.09 (4H, m), 2.18 (3H, s), 2.28 (2H, d), 2.37 (2H, t), 2.67 - 2.74 (2H, m), 2.92 - 3.09 (2H, m), 3.49 - 3.58 (3H, m), 4.35 - 4.42 (1H, m), 6.87 (1H, d), 7.06 - 7.12 (2H, m)
88	Methyl 4-[[4-(4-chloro-2-methylphenoxy)-1-piperidinyl]methyl]- α , α -dimethyl-1-piperidinepropanoate	437/439	
89	Methyl 4-[[4-(2,4-dichloro-3-methylphenoxy)-1-piperidinyl]methyl]- α , α -dimethyl-1-piperidinepropanoate	471/473	
91	4-[[4-(4-Chloro-2-methylphenoxy)-1-piperidinyl]methyl]- α , α -dimethyl-1-piperidinepropanoic acid	423/425	$\delta_{(CD_3OD)}$ 1.14 (6H, s), 1.32 - 1.47 (2H, m), 1.65 - 1.80 (3H, m), 1.92 (4H, d), 2.08 (3H, s), 2.22 (2H, d), 2.27 - 2.36 (2H, m), 2.59 - 2.68 (2H, m), 2.86 - 2.99 (4H, m), 3.37 - 3.45 (2H, m), 4.26 - 4.34 (1H, m), 6.78 (1H, d), 6.97 (1H, d), 7.01 (1H, q)

92	4-[[4-(2,4-Dichloro-3-methylphenoxy)-1-piperidiny][methyl]- α , α -dimethyl-1-piperidinepropanoic acid	457/459	$\delta_{(\text{CD}_3\text{OD} + \text{NaOD})}$ 1.10 (6H, s), 1.21 - 1.36 (4H, m), 1.59 - 1.70 (2H, m), 1.77 - 1.87 (2H, m), 1.93 - 2.02 (2H, m), 2.04 - 2.13 (2H, m), 2.18 - 2.23 (2H, m), 2.29 - 2.38 (1H, m), 2.44 (3H, s), 2.48 (2H, s), 2.64 - 2.73 (2H, m), 2.87 - 2.93 (2H, m), 4.41 - 4.48 (1H, m), 6.94 (1H, d), 7.24 (1H, d)
95	Methyl 4-[[4-(3,4-dichlorophenoxy)-1-piperidiny][methyl]-1-piperidinepentanoate	457/459	
96	Ethyl 4-[[4-(3,4-dichlorophenoxy)-1-piperidiny][methyl]-1-piperidinehexanoate	485/487	
97	4-[[4-(3,4-Dichlorophenoxy)-1-piperidiny][methyl]-1-piperidinebutanoic acid	429/431	$\delta_{(\text{CD}_3\text{OD} + \text{NaOD})}$ 1.08 - 1.26 (2H, m), 1.42 - 1.53 (1H, m), 1.61 - 1.77 (6H, m), 1.85 - 1.97 (4H, m), 2.05 (2H, t), 2.13 (2H, d), 2.17 - 2.24 (2H, m), 2.24 - 2.32 (2H, m), 2.56 - 2.66 (2H, m), 2.87 (2H, d), 4.24 - 4.32 (1H, m), 6.78 (1H, dd), 6.99 (1H, d), 7.27 (1H, d)

98	4-[[4-(3,4-Dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinepentanoic acid	443/445	$\delta_{(\text{CD}_3\text{OD} + \text{NaOD})}$ 1.15-1.29 (1H, m), 1.36 (2H, q), 1.55 - 1.62 (2H, m), 1.62 - 1.72 (4H, m), 1.86 - 1.98 (4H, m), 2.16 (2H, t), 2.22 (2H, d), 2.28 (2H, t), 2.61 - 2.70 (2H, m), 2.78 (2H, t), 2.93 (2H, t), 3.36 - 3.44 (2H, m), 4.27 - 4.34 (1H, m), 6.79 (1H, dd), 7.00 (1H, d), 7.28 (1H, d)
99	4-[[4-(3,4-Dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinehexanoic acid	457/459	$\delta_{(\text{CD}_3\text{OD} + \text{NaOD})}$ 1.22 - 1.42 (4H, m), 1.49 - 1.71 (5H, m), 1.74 - 1.85 (4H, m), 1.94 - 2.07 (4H, m), 2.14 - 2.27 (4H, m), 2.29 - 2.40 (4H, m), 2.67 - 2.77 (2H, m), 2.93 - 3.01 (2H, m), 4.35 - 4.44 (1H, m), 6.90 (1H, dd), 7.10 (1H, d), 7.39 (1H, d)
101	4-(3,4-Dichlorophenoxy)-1-[[1-[2-(2H-tetrazol-5-yl)ethyl]-4-piperidinyl]methyl]-piperidine	439/441	$\delta_{(\text{CD}_3\text{OD})}$ 1.35 (2H, dd), 1.66 - 1.76 (2H, m), 1.77 - 1.84 (1H, m), 1.88 - 1.99 (4H, m), 2.31 (2H, d), 2.34 - 2.46 (2H, m), 2.66 - 2.89 (4H, m), 3.12 - 3.18 (2H, m), 3.24 - 3.36 (2H, m), 3.45 (2H, d), 4.19 - 4.43 (1H, m), 6.80 (1H, dd), 7.02 (1H, d), 7.29 (1H, d)
103	N-[3-[4-[[4-(3,4-Dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]propyl]-1,1,1-trifluoro-methanesulfonamide	532/534	$\delta_{(\text{CD}_3\text{OD})}$ 1.14 - 1.30 (2H, m), 1.53 - 1.76 (5H, m), 1.80 (2H, d), 1.86 - 1.97 (2H, m), 2.18 (2H, d), 2.21 - 2.34 (4H, m), 2.64 (4H, t), 3.10 (2H, d), 3.17 (2H, t), 4.20 - 4.40 (1H, m), 6.79 (1H, dd), 7.00 (1H, d), 7.28 (1H, d)

104	<i>N</i> -[2-[4-[[4-(3,4-Dichloro-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]ethyl]-1,1,1-trifluoromethanesulfonamide,	532/534	$\delta_{\text{(CD}_3\text{OD)}}$ 1.27 - 1.43 (2H, m), 1.69 - 1.81 (1H, m), 1.82 - 1.92 (4H, m), 1.99 - 2.10 (2H, m), 2.32 (3H, s), 2.39 - 2.48 (4H, m), 2.51 - 2.62 (2H, m), 2.77 (2H, t), 2.80 - 2.89 (2H, m), 3.19 (2H, d), 3.36 (2H, t), 4.43 - 4.53 (1H, m), 6.92 (1H, d), 7.28 (1H, d)
-----	--	---------	--

EXAMPLE 105

Pharmacological Analysis: Calcium flux [Ca^{2+}]_i assay

Human eosinophils

Human eosinophils were isolated from EDTA anticoagulated peripheral blood as previously described (Hansel et al., *J. Immunol. Methods*, 1991, 145, 105-110). The cells were resuspended ($5 \times 10^6 \text{ mL}^{-1}$) and loaded with $5 \mu\text{M}$ FLUO-3/AM + Pluronic F127 $2.2 \mu\text{L/mL}$ (Molecular Probes) in low potassium solution (LKS; NaCl 118mM, MgSO_4 0.8mM, glucose 5.5mM, Na_2CO_3 8.5mM, KCl 5mM, HEPES 20mM, CaCl_2 1.8mM, BSA 0.1%, pH 7.4) for one hour at room temperature. After loading, cells were centrifuged at 200g for 5min and resuspended in LKS at $2.5 \times 10^6 \text{ mL}^{-1}$. The cells were then transferred to 96 well FLIPr plates (Poly-D-Lysine plates from Becton Dickinson pre-incubated with $5 \mu\text{M}$ fibronectin for two hours) at $25 \mu\text{L/well}$. The plate was centrifuged at 200g for 5min and the cells were washed twice with LKS ($200 \mu\text{L}$; room temperature).

A compound of the Examples was pre-dissolved in DMSO and added to a final concentration of 0.1%(v/v) DMSO. Assays were initiated by the addition of an A_{30} concentration of eotaxin and the transient increase in fluo-3 fluorescence ($\text{I}_{\text{Ex}} = 490\text{nm}$ and $\text{I}_{\text{Em}} = 520\text{nm}$) monitored using a FLIPR (Fluorometric Imaging Plate Reader, Molecular Devices, Sunnyvale, U.S.A.).

Compounds of the Examples were found to be antagonists if the increase in fluorescence induced by eotaxin (a selective CCR3 agonist) was inhibited in a concentration dependent manner. The concentration of antagonist required to inhibit the fluorescence by 50% can be used to determine the IC_{50} for the antagonist at the CCR3 receptor.

EXAMPLE 106

Human eosinophil chemotaxis

Human eosinophils were isolated from EDTA anticoagulated peripheral blood as previously described (Hansel et al., *J. Immunol. Methods*, 1991, 145, 105-110). The cells were resuspended at $10 \times 10^6 \text{ mL}^{-1}$ in RPMI containing 200 IU/mL penicillin, $200 \mu\text{g/mL}$ streptomycin sulfate and supplemented with 10% HIFCS, at room temperature.

Eosinophils ($700 \mu\text{L}$) were pre-incubated for 15 mins at 37°C with $7 \mu\text{L}$ of either vehicle or compound (100x required final concentration in 10% DMSO). The chemotaxis

plate (ChemoTx, 3µm pore, Neuroprobe) was loaded by adding 28µl of a concentration of eotaxin 0.1 to 100nM (a selective CCR3 agonist over this concentration range) containing a concentration of a compound according to the Examples or solvent to the lower wells of the chemotaxis plate. The filter was then placed over the wells and 25 µl of eosinophil
5 suspension were added to the top of the filter. The plate was incubated for 1 hr at 37° C in a humidified incubator with a 95% air/5% CO₂ atmosphere to allow chemotaxis.

The medium, containing cells that had not migrated, was carefully aspirated from above the filter and discarded. The filter was washed once with phosphate buffered saline (PBS) containing 5 mM EDTA to remove any adherent cells. Cells that had migrated
10 through the filter were pelleted by centrifugation (300xg for 5 mins at room temperature) and the filter removed and the supernatant transferred to each well of a 96-well plate (Costar). The pelleted cells were lysed by the addition of 28 µl of PBS containing 0.5% Triton x100 followed by two cycles of freeze/thawing. The cell lysate was then added to the supernatant. The number of eosinophils migrating was quantified according to the
15 method of Strath et al., *J. Immunol. Methods*, 1985, 83, 209 by measuring eosinophil peroxidase activity in the supernatant.

Compounds of the Examples were found to be antagonists of eotaxin mediated human eosinophil chemotaxis if the concentration response to eotaxin was shifted to the right of the control curve. Measuring the concentration of eotaxin required to give 50%
20 chemotaxis in the presence or absence of compounds enables the apparent affinity of the compounds at CCR3 to be calculated.

Example	% inhibition at 1µM
1	96
4	90
10	108
13	87

EXAMPLE 107

25 Guinea-pig isolated trachea

(See for example, Harrison, R.W.S., Carswell, H. & Young, J.M. (1984) *European J. Pharmacol.*, 106, 405-409.)

Male albino Dunkin-Hartley guinea-pigs (250g) were killed by cervical dislocation and the whole trachea removed. After clearing the adherent connective tissue, the trachea was cut into six ring segments each three cartilage bands wide and then suspended in 20 mL organ baths containing Krebs-Henseleit solution of the following composition (mM): NaCl 117.6, NaH₂PO₄ 0.9, NaHCO₃ 25.0, MgSO₄ 1.2, KCl 5.4, CaCl₂ 2.6 and glucose 11.1. The buffer was maintained at 37°C and gassed with 5% CO₂ in oxygen. Indomethacin (2.8µM) was added to the Krebs solution to prevent development of smooth muscle tone due to the synthesis of cyclo-oxygenase products. The tracheal rings were suspended between two parallel tungsten wire hooks, one attached to an Ormed beam isometric force transducer and the other to a stationary support in the organ bath. Changes in isometric force were recorded on 2-channel Sekonic flat bed chart recorders.

Experimental protocols

At the beginning of each experiment a force of 1g was applied to the tissues and this was reinstated over a 60 minute equilibration period until a steady resting tone was achieved. Subsequently, a cumulative histamine concentration effect (E/[A]) curve was constructed at 0.5 log₁₀ unit increments, in each tissue. The tissues were then washed and approximately 30 minutes later, test compound or vehicle (20% DMSO) was added. Following an incubation period of 60 minutes a second E/[A] curve was performed to histamine.

Contraction responses were recorded as a percentage of the first curve maximum.

Data analysis

Experimental E/[A] curve data were analysed for the purposes of estimating the potencies (p[A₅₀] values) of histamine in the absence and presence of the test compound. Affinity (pA₂) values of test compounds were subsequently calculated using the following equation:

$$\log(r-1) = \log[B] + pA_2$$

where $r = [A]_{50}$ in presence of test compound/[A]₅₀ in absence of antagonist and [B] is the concentration of test compound. Compounds of the Examples were found to be H1 antagonists.


EXAMPLE 108

Histamine H1 receptor binding activity of compounds of the invention was assessed by competition displacement of 1nM [3H]-pyrilamine (Amersham, Bucks, Product code TRK 608, specific activity 30Ci/mmol) to 2µg membranes prepared from recombinant CHO-K1 cells expressing the human H1 receptor (Euroscreen SA, Brussels,

Belgium, product code ES-390-M) in assay buffer (50mM Tris pH 7.4 containing 2mM MgCl₂, 250mM sucrose and 100mM NaCl) for 1 hour at room temperature.


Example	H1 pKi /[1328_S]
1	7.2
2	7.5
3	7.4
4	7.0
5	7.1
6	7.7
7	7.1
8	7.3
9	7.5
10	6.6
11	6.8
12	6.7
13	7.6
14	7.6
15	7.6
17	8.0
18	7.8
19	8.1
42	8.0
69	6.9
77	6.9
78	6.7
82	7.0
84	6.7
100	7.4
103	7.7

Scheme 1

To prepare compounds of formula (I) wherein Z is CO_2R^3 

CLAIMS

1. A compound of formula (I):



5 wherein:

X is CH₂, C(O), O, S, S(O), S(O)₂ or NR³;

Y is a bond, C₁₋₆ alkylene (optionally substituted by C₁₋₄ alkyl or phenyl),
phenylene (optionally substituted by halogen, hydroxy, C₁₋₄ alkyl or C₁₋₄ alkoxy) or
heterocyclylene (optionally substituted by halogen, hydroxy, C₁₋₄ alkyl or C₁₋₄
10 alkoxy);

Z is CO₂R^b, NHS(O)₂CF₃, S(O)₂OH, OCH₂CO₂R^b or tetrazolyl;

R¹ is hydrogen, C₁₋₆ alkyl, aryl or heterocyclyl;

R² is hydrogen, C₁₋₆ alkyl, aryl or heterocyclyl;

15 R^a and R^b are, independently, hydrogen or C₁₋₄ alkyl; or when R² is aryl or
heterocyclyl R^a may be C₂₋₃ alkylene forming a ring with an ortho position on R²;
R^c is hydrogen or hydroxy;

wherein, unless stated otherwise, the foregoing aryl and heterocyclyl moieties are
optionally substituted by: halogen, cyano, nitro, hydroxy, oxo, S(O)_pR⁴,

OC(O)NR⁵R⁶, NR⁷R⁸, NR⁹C(O)R¹⁰, NR¹¹C(O)NR¹²R¹³, S(O)₂NR¹⁴R¹⁵,

20 NR¹⁶S(O)₂R¹⁷, C(O)NR¹⁸R¹⁹, C(O)R²⁰, CO₂R²¹, NR²²CO₂R²³, C₁₋₆ alkyl, CF₃, C₁₋₆
alkoxy(C₁₋₆)alkyl, C₁₋₆ alkoxy, OCF₃, C₁₋₆ alkoxy(C₁₋₆)alkoxy, C₁₋₆ alkylthio, C₂₋₆
alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl (itself optionally substituted by C₁₋₄ alkyl or
oxo), methylenedioxy, difluoromethylenedioxy, phenyl, phenyl(C₁₋₄)alkyl,
phenoxy, phenylthio, phenyl(C₁₋₄)alkoxy, heterocyclyl, heterocyclyl(C₁₋₄)alkyl,

25 heterocycliloxy or heterocyclyl(C₁₋₄)alkoxy; wherein any of the immediately
foregoing phenyl and heterocyclyl moieties are optionally substituted with halogen,
hydroxy, nitro, S(O)_q(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl), S(O)₂N(C₁₋₄
alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁵ and R⁶
below), cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, C(O)NH₂, C(O)NH(C₁₋₄ alkyl), C(O)N(C₁₋₄
30 alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁵ and R⁶

below), CO_2H , $\text{CO}_2(\text{C}_{1-4} \text{ alkyl})$, $\text{NHC}(\text{O})(\text{C}_{1-4} \text{ alkyl})$, $\text{NHS}(\text{O})_2(\text{C}_{1-4} \text{ alkyl})$,
 $\text{C}(\text{O})(\text{C}_{1-4} \text{ alkyl})$, CF_3 or OCF_3 ;


p and q are, independently, 0, 1 or 2;

- 5 $\text{R}^3, \text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{R}^{10}, \text{R}^{11}, \text{R}^{12}, \text{R}^{13}, \text{R}^{14}, \text{R}^{15}, \text{R}^{16}, \text{R}^{18}, \text{R}^{19}, \text{R}^{20}, \text{R}^{21}$ and R^{22} are,
independently, hydrogen, C_{1-6} alkyl (optionally substituted by halogen, hydroxy or
 C_{3-10} cycloalkyl), $\text{CH}_2(\text{C}_{2-6} \text{ alkenyl})$, phenyl (itself optionally substituted by
halogen, hydroxy, nitro, NH_2 , $\text{NH}(\text{C}_{1-4} \text{ alkyl})$, $\text{N}(\text{C}_{1-4} \text{ alkyl})_2$ (and these alkyl groups
may join to form a ring as described for R^5 and R^6 below), $\text{S}(\text{O})_2(\text{C}_{1-4} \text{ alkyl})$,
 $\text{S}(\text{O})_2\text{NH}_2$, $\text{S}(\text{O})_2\text{NH}(\text{C}_{1-4} \text{ alkyl})$, $\text{S}(\text{O})_2\text{N}(\text{C}_{1-4} \text{ alkyl})_2$ (and these alkyl groups may
10 join to form a ring as described for R^5 and R^6 below), cyano, C_{1-4} alkyl, C_{1-4} alkoxy,
 $\text{C}(\text{O})\text{NH}_2$, $\text{C}(\text{O})\text{NH}(\text{C}_{1-4} \text{ alkyl})$, $\text{C}(\text{O})\text{N}(\text{C}_{1-4} \text{ alkyl})_2$ (and these alkyl groups may join
to form a ring as described for R^5 and R^6 below), CO_2H , $\text{CO}_2(\text{C}_{1-4} \text{ alkyl})$,
 $\text{NHC}(\text{O})(\text{C}_{1-4} \text{ alkyl})$, $\text{NHS}(\text{O})_2(\text{C}_{1-4} \text{ alkyl})$, $\text{C}(\text{O})(\text{C}_{1-4} \text{ alkyl})$, CF_3 or OCF_3) or
heterocyclyl (itself optionally substituted by halogen, hydroxy, nitro, NH_2 , $\text{NH}(\text{C}_{1-4}$
15 $\text{alkyl})$, $\text{N}(\text{C}_{1-4} \text{ alkyl})_2$ (and these alkyl groups may join to form a ring as described
for R^5 and R^6 below), $\text{S}(\text{O})_2(\text{C}_{1-4} \text{ alkyl})$, $\text{S}(\text{O})_2\text{NH}_2$, $\text{S}(\text{O})_2\text{NH}(\text{C}_{1-4} \text{ alkyl})$,
 $\text{S}(\text{O})_2\text{N}(\text{C}_{1-4} \text{ alkyl})_2$ (and these alkyl groups may join to form a ring as described for
 R^5 and R^6 below), cyano, C_{1-4} alkyl, C_{1-4} alkoxy, $\text{C}(\text{O})\text{NH}_2$, $\text{C}(\text{O})\text{NH}(\text{C}_{1-4} \text{ alkyl})$,
 $\text{C}(\text{O})\text{N}(\text{C}_{1-4} \text{ alkyl})_2$ (and these alkyl groups may join to form a ring as described for
20 R^5 and R^6 below), CO_2H , $\text{CO}_2(\text{C}_{1-4} \text{ alkyl})$, $\text{NHC}(\text{O})(\text{C}_{1-4} \text{ alkyl})$, $\text{NHS}(\text{O})_2(\text{C}_{1-4}$
 $\text{alkyl})$, $\text{C}(\text{O})(\text{C}_{1-4} \text{ alkyl})$, CF_3 or OCF_3);
alternatively NR^5R^6 , NR^7R^8 , $\text{NR}^{12}\text{R}^{13}$, $\text{NR}^{14}\text{R}^{15}$, $\text{NR}^{18}\text{R}^{19}$, may, independently,
form a 4-7 membered heterocyclic ring, azetidine, pyrrolidine, piperidine, azepine,
morpholine or piperazine, the latter optionally substituted by C_{1-4} alkyl on the distal
25 nitrogen;
 R^4 , R^{17} and R^{23} are, independently, C_{1-6} alkyl (optionally substituted by halogen,
hydroxy or C_{3-10} cycloalkyl), $\text{CH}_2(\text{C}_{2-6} \text{ alkenyl})$, phenyl (itself optionally substituted
by halogen, hydroxy, nitro, NH_2 , $\text{NH}(\text{C}_{1-4} \text{ alkyl})$, $\text{N}(\text{C}_{1-4} \text{ alkyl})_2$ (and these alkyl
groups may join to form a ring as described for R^5 and R^6 above), $\text{S}(\text{O})_2(\text{C}_{1-4} \text{ alkyl})$,
30 $\text{S}(\text{O})_2\text{NH}_2$, $\text{S}(\text{O})_2\text{NH}(\text{C}_{1-4} \text{ alkyl})$, $\text{S}(\text{O})_2\text{N}(\text{C}_{1-4} \text{ alkyl})_2$ (and these alkyl groups may
join to form a ring as described for R^5 and R^6 above), cyano, C_{1-4} alkyl, C_{1-4} alkoxy,
 $\text{C}(\text{O})\text{NH}_2$, $\text{C}(\text{O})\text{NH}(\text{C}_{1-4} \text{ alkyl})$, $\text{C}(\text{O})\text{N}(\text{C}_{1-4} \text{ alkyl})_2$ (and these alkyl groups may
join to form a ring as described for R^5 and R^6 above), CO_2H , $\text{CO}_2(\text{C}_{1-4} \text{ alkyl})$,


- NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl), C(O)(C₁₋₄ alkyl), CF₃ or OCF₃) or heterocyclyl (itself optionally substituted by halogen, hydroxy, nitro, NH₂, NH(C₁₋₄ alkyl), N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁵ and R⁶ above), S(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl),
- 5 S(O)₂N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁵ and R⁶ above), cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, C(O)NH₂, C(O)NH(C₁₋₄ alkyl), C(O)N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R⁵ and R⁶ above), CO₂H, CO₂(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl), C(O)(C₁₋₄ alkyl), CF₃ or OCF₃);
- 10 or an N-oxide thereof; or a pharmaceutically acceptable salt thereof; or a solvate thereof.
2. A compound as claimed in claim 1 wherein R¹ is phenyl optionally substituted with halogen, C₁₋₄ alkyl or C₁₋₄ alkoxy.
- 15 3. A compound as claimed in claim 1 or 2 wherein X is O.
4. A compound as claimed in claim 1, 2 or 3 wherein R^a and R^b are both hydrogen.
- 20 5. A compound as claimed in claim 1, 2, 3 or 4 wherein Z is CO₂R^b.
6. A compound as claimed in claim 1, 2, 3, 4 or 5 wherein Y is a bond or alkylene (optionally substituted by C₁₋₄ alkyl); R^a is hydrogen; and, R² is hydrogen, C₁₋₆ alkyl, phenyl (optionally substituted by halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy or
- 25 NHC(O)(C₁₋₄ alkyl)) or heterocyclyl (optionally substituted by halogen, C₁₋₄ alkyl or C₁₋₄ alkoxy).
7. A compound as claimed in claim 1, 2, 3, 4 or 5 wherein Y is phenylene (optionally substituted by halogen, C₁₋₄ alkyl or C₁₋₄ alkoxy) or heterocyclylene (optionally substituted by halogen, C₁₋₄ alkyl or C₁₋₄ alkoxy); R^a is hydrogen; and R² is
- 30 hydrogen or C₁₋₄ alkyl.

8. A process for preparing a compound of formula (I) as claimed in claim 1, the process comprising:

a) coupling a compound of formula (II):




5 with a compound of formula (III):



wherein L is a suitable leaving group;



- b) when Rᵃ is hydrogen and Z is CO₂Rᵇ, reductive amination of a compound (II) with a compound of formula (IV):



10


wherein Rᵇ is C₁-₄ alkyl, in the presence of NaBH(OAc)₃ and acetic acid, or NaBH₃CN in a suitable solvent, optionally followed by hydrolysis of the ester group;

- 15 c) when Y is a bond, Rᵃ and Rᵇ are both hydrogen and Z is CO₂H, a three component coupling of a compound of formula (II) with compounds of formula (V) and (VI):




in a suitable solvent at a suitable elevated temperature;

- 20 d) when Y is a bond and Z is CO₂H, performing a nitrile hydrolysis on a compound of formula (XI):



- e) when Z is tetrazol-5-yl, reacting a compound of formula (XI) with $(\text{CH}_3)_3\text{SiN}_3$ and $(\text{Bu}_3\text{Sn})_2\text{O}$ at an elevated temperature;
- f) when Z is $\text{NHS}(\text{O})_2\text{CF}_3$, reacting a compound of formula (XII):



5 with triflic anhydride at a reduced temperature.

9. A pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt thereof or solvate thereof as claimed in claim 1, and a pharmaceutically acceptable adjuvant, diluent or carrier.
- 10 10. A compound of the formula (I), or a pharmaceutically acceptable salt thereof or solvate thereof as claimed in claim 1, for use in therapy.
11. A compound of formula (I), or a pharmaceutically acceptable salt thereof or solvate thereof as claimed in claim 1, in the manufacture of a medicament for use in therapy.
- 15 12. A method of treating a chemokine mediated disease state in a mammal suffering from, or at risk of, said disease, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof or solvate thereof as claimed in claim 1.
- 20

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 03/01425

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07D 401/06, C07D 401/14, A61K 31/4545, A61P 1/04, A61P 11/00, A61P 17/00, A61P 19/02, A61P 27/00, 29/00, 37/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07D, A61K, A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, WPI DATA, CHEM. ABS DATA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 0035877 A1 (DU PONT PHARMACEUTICALS COMPANY), 22 June 2000 (22.06.00)	1-12

X	WO 0177101 A1 (ASTRAZENECA AB), 18 October 2001 (18.10.01)	1-12

X	WO 0000488 A1 (SCHERING CORPORATION), 6 January 2000 (06.01.00)	1-12

X	WO 9801425 A1 (SCHERING CORPORATION), 15 January 1998 (15.01.98)	1-12



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"B" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z" document member of the same patent family

Date of the actual completion of the international search

19 December 2003

Date of mailing of the international search report

23-12-2003

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Viveca Norén/Eö
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 03/01425

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9806697 A1 (SCHERING CORPORATION), 19 February 1998 (19.02.98) ---	1-12
X	WO 02081449 A1 (NOVARTIS AG), 17 October 2002 (17.10.02) ---	1-12
X	EP 1076055 A1 (DAINIPPON PHARMACEUTICAL CO., LTD.), 14 February 2001 (14.02.01) -----	1-12

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE03/01425

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 12
because they relate to subject matter not required to be searched by this Authority, namely:
see next sheet
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically;
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE03/01425

Claims 12 relates to methods of treatment of the human or animal body by surgery or by therapy or diagnostic methods practised on the human or animal body (PCT Rule 39.1(iv)). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds or compositions.

INTERNATIONAL SEARCH REPORT

Information on patent family members

31/10/03

International application No.

PCT/SE 03/01425

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0035877 A1	22/06/00	AU 2056800 A	03/07/00
		CA 2347912 A	22/06/00
		EP 1140834 A	10/10/01
		US 6036057 A	14/03/00
		US 6331545 B	18/12/01
		US 2002119980 A	29/08/02
WO 0177101 A1	18/10/01	AU 4699701 A	23/10/01
		BR 0109922 A	18/02/03
		CA 2403012 A	18/10/01
		CN 1433411 T	30/07/03
		EP 1274701 A	15/01/03
		GB 0008626 D	00/00/00
		NO 20024774 A	29/11/02
		US 6525070 B	25/02/03
		US 2002077337 A	20/06/02
		GB 0019111 D	00/00/00
WO 0000488 A1	06/01/00	SE 0003664 D	00/00/00
		AU 756484 B	16/01/03
		AU 1714400 A	05/06/00
		AU 4820199 A	17/01/00
		CA 2336000 A	06/01/00
		CN 1314905 T	26/09/01
		EP 1091956 A	18/04/01
		EP 1131041 A	12/09/01
		HU 0104058 A	28/03/02
		IL 140249 D	00/00/00
		JP 3344997 B	18/11/02
		JP 2002519349 T	02/07/02
		JP 2002529487 T	10/09/02
		NZ 508910 A	31/01/03
		TW 474933 B	00/00/00
		US 6607715 B	19/08/03
		US 2003012763 A	16/01/03
		WO 0028950 A	25/05/00
		ZA 200007555 A	15/03/02

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

31/10/03

PCT/SE 03/01425

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9801425 A1	15/01/98	AT 227708 T	15/11/02
		AU 728592 B	11/01/01
		AU 3581097 A	02/02/98
		CA 2259655 A,C	15/01/98
		DE 69717109 D,T	30/04/03
		DK 912515 T	10/03/03
		EP 0912515 A,B	06/05/99
		SE 0912515 T3	
		ES 2182104 T	01/03/03
		HU 9904622 A	28/06/00
		IL 127942 D	00/00/00
		JP 3068206 B	24/07/00
		JP 11514671 T	14/12/99
		KR 2000023599 A	25/04/00
		NZ 333513 A	28/04/00
		PT 912515 T	31/03/03
WO 9806697 A1	19/02/98	AU 732096 B	12/04/01
		AU 3973297 A	06/03/98
		BR 9711061 A	17/08/99
		CN 1232453 A	20/10/99
		CZ 9900433 A	14/07/99
		EP 0922029 A	16/06/99
		HU 9904363 A	28/11/00
		IL 128524 D	00/00/00
		JP 3390179 B	24/03/03
		JP 2000500786 T	25/01/00
		KR 2000029976 A	25/05/00
		NO 990671 A	15/04/99
		NZ 334017 A	28/04/00
		PL 331536 A	19/07/99
		SK 20199 A	13/03/00
		TR 9900314 T	00/00/00
WO 02081449 A1	17/10/02	GB 0108876 D	00/00/00
EP 1076055 A1	14/02/01	AU 746406 B	02/05/02
		AU 3171699 A	16/11/99
		BR 9909991 A	26/12/00
		CA 2330475 A	04/11/99
		HU 0101511 A	28/09/01
		IL 138568 D	00/00/00
		NO 20005430 A	20/12/00
		NZ 507119 A	28/08/02
		PL 343726 A	10/09/01
		SK 15852000 A	11/06/01
		US 6294555 B	25/09/01
		CN 1118452 B	20/08/03
		CN 1298391 T	06/06/01
		WO 9955674 A	04/11/99
		ZA 200005017 A	30/05/01
		JP 2000080081 A	21/03/00

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ BLACK BORDERS

☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☒ FADED TEXT OR DRAWING

☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☐ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.